



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00		A2	(11) International Publication Number: WO 98/56811
			(43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/EP98/03662 (22) International Filing Date: 9 June 1998 (09.06.98) (30) Priority Data: P 9701292 12 June 1997 (12.06.97) ES (71) Applicant (for all designated States except US): CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS [ES/ES]; Serrano, 113, E-28006 Madrid (ES). (72) Inventors; and (75) Inventors/Applicants (for US only): GUTIERREZ-ARMENTA, Crisanto [ES/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). QI, Xie [CN/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). SANZ-BURGOS, Andrés [ES/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). (74) Agent: UNGRIA-LOPEZ, Javier; Ungria Patentes y Marcas, S.A., Avenida Ramón y Cajal, 78, E-28043 Madrid (ES).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: PLANT GRAB PROTEINS			
(57) Abstract			
<p>A method of controlling plant cell and plant virus growth and/or replication, plant cell cycle, differentiation, development and/or senescence is provided characterised in that it comprises increasing or decreasing the levels or binding capabilities of GRAB (Geminivirus RepA Binding) proteins other than Rb (Retinoblastoma) proteins within plant cells.</p>			
<p>The image shows a gel electrophoresis result with four rows of bands. The first row is labeled GRAB1, the second GRAB2, the third H4, and the fourth rRNA. The columns are labeled Leaves, Roots, and Cultured cells. GRAB1 and GRAB2 bands are present in all three lanes. H4 bands are present in all three lanes. rRNA bands are present in all three lanes.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PLANT GRAB PROTEINS

The present invention relates to methods of controlling plant cell cycle, particularly for the purpose of controlling plant cell and plant virus growth and/or replication, differentiation, development and/or senescence; to use of previously
5 unidentified and/or unisolated proteins and/or nucleic acids in such methods; to use of known proteins and nucleic acids of previously unknown native function in such methods; to the unidentified and/or unisolated proteins and nucleic acids *per se* and in enriched, isolated, cell free and/or recombinant form; and to plants comprising such recombinant nucleic acids.

10 It has been well documented that successful completion of viral replication cycles within the infected cell usually requires the participation of cellular factors. This is particularly evident in the case of viruses with small genomes that encode just a few proteins. For example, animal DNA tumor viruses use the cellular machinery for their transcriptional and DNA replication processes. In addition one or more virally-encoded
15 proteins have evolved that directly impinge on the infected cell physiology to create a cellular environment appropriate for viral replication. One typical example is that of the oncoproteins encoded by animal DNA tumor viruses, i. e., SV40 T antigen, adenovirus E1A or human papilloma virus E7 proteins, which activate cell cycle in the infected cell by interfering with the retinoblastoma pathway (26, 28, 45).

20 A similar strategy seems to have evolved in plant geminiviruses, a unique group of plant DNA viruses. The geminivirus genome consists of 1 or 2 small (2.6-3.0 kb) circular single-stranded DNA molecules, depending on the subgroups (11, 24). Wheat dwarf geminivirus (WDV) belongs to subgroup I whose members have the smallest genome, a single ssDNA molecule, 2750 nucleotides in length, which encodes only a
25 few proteins. Among them, RepA (also called CI) and Rep (also called CI:C2) are the only WDV proteins required for viral transcription and replication (24). RepA is translated from the single transcript produced under the control of the complementary-sense promoter. After a splicing event of this mRNA, the Rep protein is produced (37). WDV Rep, absolutely required for viral DNA replication and this is homologous to the
30 Rep proteins of all geminiviruses. Geminivirus Rep has been shown to have DNA nicking-joining activity in vitro, origin-recognition ability and ATPase activity. However, RepA protein is unique to the WDV geminivirus subgroup and has been

implicated in modulation of Rep activity, binding to plant retinoblastoma (Rb) protein (45, 46) and stimulation of virion-sense gene expression. In addition, we have recently shown that in WDV, the Rb-binding protein (RepA) and the initiator protein (Rep) seem to play coordinate roles during viral DNA replication.

5 Geminivirus DNA replication occurs in the nucleus of the infected cells and, due to the lack of replicative enzymes encoded by the viral genome, it requires S-phase functions. Consistent with this is the accumulation of replicative intermediates in S-phase nuclei (1). Geminiviruses normally infect non-proliferating cells but, interestingly, they induce the appearance of cellular proteins typical of S-phase, such as
10 proliferating cell nuclear antigen (PCNA) (29) which is otherwise undetectable in non-proliferating cells. Subgroup I geminiviruses such as WDV encode proteins containing a LXCXE motif in the RepA protein, which mediates its ability to interact with Rb, involved in the mechanism by which geminiviruses impinge on the cell cycle activation circuit (45). These observations served the basis to isolate a full-length cDNA encoding
15 ZmRb1, a plant Rb protein, which could act in plant cells as a regulator of the G1/S transit (46). Consistent with this function, overexpression of plant Rb (as well as human Rb) in cultured plant cells significantly inhibits WDV DNA replication (45, 46). Therefore, it seems that at least one of the mechanisms used by geminiviruses to favour DNA replication is the triggering of an S-phase in the infected cell by sequestering Rb
20 and, consequently, by interfering with its negative cell growth activity.

Regulation of cell cycle, growth and differentiation in plants is the result of a complex interplay of regulators whose activity is the response to a wide variety of signals such as hormones, nutrient availability or environmental conditions (20, 39). For example, a rapid increase in the levels of D-type cyclin mRNAs occurs in response
25 to sucrose or cytokinin treatment (41) while those of the cyclin-dependent kinase (cdc2) mRNAs depends on the presence of auxin. The molecular nature of other plant cell cycle regulators as well as their function in connection to cell growth and differentiation remains largely unknown. Therefore, it is important to identify the cellular factors involved in these control pathways to elucidate the molecular mechanisms governing
30 the response of plant cells to growth signals.

Due to the absolute requirement for cellular factors to complete geminivirus replication, the present inventors postulated that geminiviruses might modulate cell

physiology by mechanisms other than the interference with the Rb pathway and that such effect might be the consequence of the targeting of, so far, unknown cellular factors by the geminivirus proteins. They have used an experimental strategy to identify proteins that interact functionally with RepA, the Rb-binding protein of WDV, and now have provided several cDNA clones encoding previously unidentified proteins and determined their function.

Based on amino acid sequence analysis, these proteins have been determined to share a common N-terminal domain, required for interaction with the viral RepA protein, while their C-terminal domains are unique to each of them. They may represent members, likely with transcriptional regulatory activity, of a much larger family of proteins related to regulators of hormone and nutrient response, meristem development and plant senescence.

Thus in a first aspect of the present invention there is provided a method of controlling plant cell cycle characterised in that it comprises increasing or decreasing the levels of GRAB (Geminivirus RepA Binding) proteins or peptides or increasing or decreasing the binding capabilities of GRAB proteins or peptides within plant cells. Such control, *inter alia*, allows control of plant cell growth and/or replication, plant virus growth within cells, plant cell differentiation, development and/or senescence. It will be understood that such proteins and peptides are other than Rb (Retinoblastoma) proteins, being particularly those described herein below with regard to the sequence listing and their functional variants.

Increasing or decreasing the levels of GRAB proteins peptides may be achieved by overproducing or underproducing the protein or peptide in a plant cell, that is, as compared to the normal level of production of the protein or peptide in the cell. Decrease of native GRAB binding activity may be achieved eg. by application of a GRAB protein or peptide binding agent, eg. such as WDV RepA or a functional part or variant thereof.

Particularly the GRAB proteins or peptides for use in this method are those comprising an amino acid sequence SEQ ID No 2 or 4 as shown herein, or a functional variant thereof that is capable of binding Geminivirus RepA. Preferred proteins or peptides have amino acid sequence homology of at least 70% with that of SEQ ID No 2 or 4, more preferably at least 90% and most preferably at least 95%. Particularly the

GRAB proteins are those in which the first 200 N-terminal amino acids are capable of binding to viral RepA protein; more preferably the first 170 N-terminal amino acids are so capable and most preferably the first 150 amino acids.

These methods may comprise the direct application of such GRAB proteins or peptides to plant cells or whole plants, but more conveniently will comprise use of the corresponding GRAB protein or peptide encoding or antisense nucleotides, ie. nucleic acids placed within the cells, particularly by use of recombinant nucleic acid, eg. recombinant DNA comprising a GRAB protein or peptide encoding sequence, positioned in the cell behind a promotor capable of supporting GRAB protein or peptide expression or production of antisense RNA. GRAB protein encoding nucleic acids can be used to produce GRAB where required, eg. ectopically in a tissue where it is not normally expressed, eg. vegetative tissue or stem tissue such as xylem or phloem. An alternative strategy might comprise expressing a GRAB protein binding peptide, eg. Geminivirus RepA, a functional variant thereof or a GRAB protein binding portion thereof, such as the C-terminal portion. Such a peptide would bind to native GRAB proteins and inhibit their activity. It will be realised that any expression of RepA, and particularly only a GRAB protein binding part thereof such as a RepA with a truncated N-terminal, in a transgenic plant other than that produce by a whole intact geminivirus would be novel. A RepA encoding cDNA in functional relationship with a promoter or other regulatory sequence in a DNA or RNA vector or DNA construct would be particularly useful for such purpose.

It will be realised that a most effective method of delivering proteins and peptides of the invention to plant cells is by expressing nucleic acid encoding *them in situ*. Such method is conventionally carried out by incorporating oligonucleotides or polynucleotides, having sequences encoding the peptide or protein, into the plant cell DNA. Such nucleotides can also be used to downregulate native GRAB expression by gene silencing coexpression (6) or through antisense strategy. By use of mutagenesis techniques, eg. such as SDM, the nucleotides of the invention may be designed and produced to encode proteins and peptides which are functional variants or otherwise overactivated or inactivated, eg. with respect to binding, of the invention.

It will be realised by those skilled in the art that suitable promoters may be active continuously or may be inducible. It will be appreciated by those skilled in the art

that inducible promoters will have advantage in so far as they are capable of providing alteration of the aforesaid GRAB protein activity only when required, eg. when viral infection is threatened, or when the plant would otherwise be particularly vulnerable, or at a particular stage of cell development. Such promoters may for example be induced
5 by environmental conditions such as stress inducing conditions, eg. reduced water availability caused by drought or freezing, or by complex entities such as plant hormones, eg. plant to plant signalling stress hormones, or by simpler entities such as particular cations or anions eg. metal cations. No particular limitation on the type of promoter to be used is envisioned.

10 Numerous specific examples of methods used to produce transgenic plants by the insertion of cDNA in conjunction with suitable regulatory sequences will be known to those skilled in the art. For example, plant transformation vectors have been described by Denecke et al (1992) EMBO J. 11, 2345-2355 and their further use to produce transgenic plants producing trehalose described in US Patent Application Serial
15 No. 08/290,301. EP 0339009 B1 and US 5250515 describe strategies for inserting heterologous genes into plants (see columns 8 to 26 of US 5250515). Electroporation of pollen to produce both transgenic monocotyledonous and dicotyledonous plants is described in US 5629183, US 7530485 and US 7350356. Further details may be found in reference works such as Recombinant Gene Expression Protocols. (1997) Edit Rocky
20 S. Tuan. Humana Press. ISBN 0-89603-333-3; 0-89603-480-1. It will be realised that no particular limitation on the type of transgenic plant to be provided is envisaged; all classes of plant, monocot or dicot, may be produced in transgenic form incorporating the nucleic acid of the invention such that GRAB activity in the plant is altered, constitutively, ectopically or temporally.

25 A preferred embodiment of the first aspect of the invention provides a method of producing or inhibiting senescence in a plant cell comprising increasing or decreasing the levels or activity of a GRAB protein or peptide, particularly a GRAB1 protein of SEQ ID No 10 or a functional variant thereof capable of inducing senescence in *N.benthamidna* plants, in a plant cell. Again such increase or decrease is most effectively
30 achieved through incorporation of nucleic acid, in this case of SEQ ID No 9, or a functional variant thereof, or may be achieved by use of RepA encoding DNA.

A second aspect of the present invention provides novel GRAB proteins or peptides *per se* and in enriched, isolated, cell free and/or recombinantly produced form. Such proteins or peptides may be naturally occurring or may be conservatively substituted homologues thereof as referred to below. Preferred proteins and peptides
5 have an N-terminal sequence having 90% or more homology to the N-terminal 200 (more preferably to the first 170 and most preferably the first 150) amino acids of GRAB1 or GRAB2 described herein, more preferably 95% or more and most preferably 98% or more. Preferred peptides comprise the sequence of the first 150 to 200 amino acids of either of these sequences or conservatively substituted variants thereof.
10 Preferred peptides comprise such a sequence without the C-terminal sequence of SENU, NAM, ATAF1 or ATAF 2 shown in Figure 4 attached hereto.

Particularly the GRAB proteins and peptides are those comprising an amino acid sequence SEQ ID No 3 or 4 as shown herein or a functional variant thereof that is capable of binding Geminivirus RepA and have amino acid sequence homology of at
15 least 70% with that of SEQ ID No 3 or 4, more preferably at least 90% and most preferably at least 98%. More preferably they comprise SEQ ID No 6 or 8 or such homology limited functional variant thereof and most preferably SEQ ID No 10 or 12 or such homology limited functional variant thereof. Where the protein or peptide comprises SEQ ID No 3 or 4 it is not of SENU, NAM, ATAF1 or ATAF2.

20 Proteins or peptides may be derived from native protein or peptide encoding DNA that has been altered by mutagenic techniques eg. using chemical mutagenesis or mutagenic PCR.

A third aspect of the present invention provides GRAB protein or peptide encoding and antisense nucleic acid *per se* and in enriched, isolated, cell free and/or
25 recombinant form. Particularly provided is consense and antisense DNA in the form of individual oligonucleotides and polynucleotides, provided that said DNA does not encode the full amino acid sequence of SENU, NAM, ATAF1 or ATAF2 as shown in Figure 4.

Specifically provided is nucleic acid, eg. in the form of a nucleotides, but
30 preferably in the form of recombinant DNA or cRNA (mRNA), that codes for the expression of the GRAB protein having an N-terminal sequence with at least 60% homology with the first 200 N-terminal amino acids of GRAB1 or GRAB2 as described

herein ; ie. its first 200 codons having such homology. Preferably the homology is at least 75% and most preferably at least 90%

Preferred nucleic acid is DNA or RNA comprising of SEQ ID No 1, 2, 5, 7, 9 or 11 or a functional variant thereof having the homology limitations referred to above.

5 More preferred is DNA of SEQ ID No 9 or 11 or a functional variant thereof.

With respect to the present specification and claims, the following technical terms are used in accordance with the definitions below unless otherwise specified.

A "functional variant" of a peptide, protein, nucleotide or polynucleotide is a peptide, protein, nucleotide or polynucleotide the amino acid or base sequence of which
10 can be derived from the amino acid or base sequence of the original peptide, protein, nucleotide or polynucleotide by the substitution, deletion and/or addition of one or more amino acid residues or bases in a way that, in spite of the change in the amino acid or base sequence, the functional variant retains at least a part of at least one of the biological activities of the original peptide, protein, nucleotide or polynucleotide in that
15 is detectable for a person skilled in the art. A functional variant is generally at least 50% homologous (i.e. the amino acid or base sequence of it is 50% identical), but advantageously at least 70% homologous and even more advantageously at least 90% homologous to the native or synthetic sequence from which it can be derived. Any functional part of a protein or a variant thereof is also termed functional variant.

20 The term "overproducing" is used herein in the most general sense possible. A special type of molecule (usually a protein, polypeptide or oligopeptide or an RNA) is said to be "overproduced" in a cell if it is produced at a level significantly and detectably higher (e.g. 20% higher) than natural level. Overproduction of a molecule in a cell can be achieved via both traditional mutation and selection techniques and genetic
25 manipulation methods.

The term "ectopic expression" is used herein to designate a special realisation of overproduction in the sense that, for example, an ectopically expressed protein is produced at a spatial point of a plant where it is naturally not at all (or not detectably) expressed, that is, said protein or peptide is overproduced at said point.

30 The term 'underproducing' is intended to cover production of peptide, polypeptide, protein or mRNA at a level significantly lower than the natural level (eg 20% or more lower), particularly to undetectable levels

The DNA or RNA of the invention may have a sequence containing degenerate substitutions in the nucleotides of the codons in the sequences encoding for GRAB proteins or peptides, eg. GRAB1 or GRAB2, and in which the RNA U's replace the T's of DNA. Preferred *per se* DNAs or RNAs are capable of hybridising with the polynucleotides encoding for GRAB1 or GRAB2 in conditions of low stringency, being preferably also capable of such hybridisation in conditions of high stringency.

The terms "conditions of low stringency" and "conditions of high stringency" are of course understood fully by those skilled in the art, but are conveniently exemplified in US 5202257, columns 9 and 10. Where modifications are made they should lead to the expression of a protein with different amino acids in the same class as the corresponding amino acids to these GRAB protein sequences; that is to say, they are conservative substitutions. Such substitutions are known to those skilled in the art (see, for example, US 5380712), and are considered only when the protein is active as a GRAB protein.

In a fourth aspect of the present invention there is provided a protein or peptide expressed by the recombinant DNA or RNA referred to in the second aspect above, new proteins or peptides derived from that DNA or RNA and protein or peptide that is produced from native DNA or RNA that has been altered by mutagenic means such as the use of mutagenic polymerase chain reaction primers. Methods of producing the proteins or peptides of the invention characterised in that they comprise use of the DNA or RNA of the invention to express them from cells are also provided in this aspect.

A fifth aspect of the present invention provides nucleic acid probes and primers complementary to any 15 or more contiguous bases of the DNA sequences identified herein below as SEQ ID No 5, 7, 9 or 11 or complementary sequences or RNA sequences corresponding thereto; particularly of the first 150 N-terminal coding DNA bases of such sequences. These probes and primers in the form of oligonucleotides and polynucleotides may also be used to identify further naturally occurring or synthetically produced GRAB peptides or proteins using eg. southern or northern blotting.

Oligonucleotides for use as probes conveniently comprise at least 18 consecutive bases of the sequences SEQ ID No 5, 7, 9 or 11 herein, preferably being of 30 to 100 bases long, but may be of any length up to the complete sequence or even longer. For use as PCR or LCR primers the oligonucleotide preferably is of 10 to 20

bases long but may be longer. Primers should be single stranded but probes may be double stranded ie. including complementary sequences.

A sixth aspect of the present invention provides vectors comprising DNA or RNA of the third aspect of the invention.

5 A seventh aspect of the present invention provides a method for producing transformed cells comprising nucleic acid of the invention comprising introducing said nucleic acid into the cell in vector form.

A eighth aspect of the present invention provides a method for producing transformed cells comprising nucleic acid of the invention comprising introducing said
10 nucleic acid into the cell directly, eg. by electroporation or particle bombardment. Particularly provided is the electroporation of pollen cells.

An ninth aspect of the present invention provides cells, particularly plant cells, eg. including pollen and seed cells, comprising the recombinant nucleic acid of the invention, particularly the DNA or RNA of the invention, and plants comprising such
15 cells.

Plasmids containing a DNA coding for expression of the GRAB proteins GRAB 1 and GRAB 2 described herein have been deposited under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms of 1977; these being deposited on 11 June 1997 at the Coleccion Espanola de Cultivos
20 Tipo, with the accession numbers CECT 4889 (this containing GRAB 1 sequence) and CECT 4890 (this containing GRAB 2 sequence).

SEQUENCE LISTING

SEQ ID No 1 and 2 show the nucleotide sequences of GRAB1 and GRAB 2
25 respectively which encode for conserved domains N1 to N5 with intervening bases marked as N.

SEQ ID No 3 and 4 show the respective amino acid sequences corresponding to SEQ ID No 1 and 2.

SEQ ID No 5 and 7 show the full nucleotide sequences spanning N1 to N5 of GRAB1
30 and GRAB2 respectively

SEQ ID No 6 and 8 show the corresponding amino acid sequences to SEQ ID No 5 and 7.

SEQ ID No 9 and 11 show the full length sequences of isolated cDNA including coding regions for GRAB1 and GRAB2 respectively.

SEQ ID No 10 and 12 show the corresponding amino acid sequences of proteins GRAB1 and GRAB2.

5

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the results of northern analysis for transcripts of GRAB 1 and GRAB 2.

Figure 2 shows the results of studies carried out to identify the region of GRAB 1 and GRAB 2 which are involved in the binding to WDV Rep A

10 Figure 3 shows the results of studies carried out to identify the region of WDV Rep A involved in the binding with GRAB proteins.

Figure 5 shows the alignment of various protein sequences, previously known and unknown, having the GRAB protein domains N1 to N5, for use in the method of the invention.

15 Figure 6 shows the charge distribution of these proteins

The present invention will now be described further by way of illustration only by reference to the following non-limiting Examples. Further embodiments falling within the scope of the claims will occur to those skilled in the art in the light of these.

20

In the Examples below the following methods were used

MATERIALS AND METHODS

DNA manipulations

Proteinase K, restriction endonucleases and other enzymes for DNA manipulations
25 were from Merck, Boehringer Mannheim, New England Biolabs and Promega. Standard DNA manipulation techniques were applied as described in [34]. DNA sequencing was carried using an Applied Biosystem automatic sequencing device. Oligonucleotides were from Isogen Bioscience BV (Maarsen, The Netherlands)

30 DNA and RNA purification

Genomic DNA and total RNA were isolated from wheat leaves, roots and suspension cultured cells by grinding the material, previously frozen in liquid nitrogen, essentially as described [41]. The powder was mixed with extraction buffer (50 mM Tris-HCl, pH 6.0, 10 mM EDTA, 2% SDS, 100 mM LiCl), and after heating at 65°C with phenol (1:1, 65°C), vortexed for 20 sec and centrifuged at 4°C for 15 min at 12000 rpm. The supernatant was extracted twice with the same volume of phenol:chloroform (1:1) and precipitated with one volume of 4M LiCl. After centrifugation, the RNA pellet was resuspended in TE buffer and two volumes of ethanol were added to the liquid phase to precipitate genomic DNA. Purification of poly(A)⁺ mRNA was carried out as described [47].

Construction of the yeast two-hybrid cDNA library from wheat cultured cells

Five micrograms of poly(A)⁺ mRNA isolated from wheat suspension cultured cells were used as a substrate for cDNA synthesis using a cDNA synthesis kit (Stratagene), according to the manufacturer's instructions. The resulting double-stranded DNA, containing EcoRI and XhoI ends, had an average size of 1.3 Kb. A sample (500 ng) of this cDNA was ligated to 750 ng of the EcoRI/XhoI-digested pGAD-GH vector (Clontech) for 48 hr at 8°C. Following ligation, the library was dialyzed against distilled water and electroporated into *E. coli* DH10B (Gibco). For convenience, the cDNA library was separated into five sub-libraries each containing ~6x10⁵ primary transformants. Total library DNA was obtained by plating primary transformants on fifty 150-mm LB plates plus ampicillin. Colonies were scrapped off into LB (+Amp) medium, and plasmid DNA was prepared as described [34].

Yeast two-hybrid screening

The yeast strain HF7c (*MATa ura3-52 his3-200 ade2-101 lys2-801 trp1-901 leu2-3,112 gal4-542 gal80-538 LYS2::GAL1UAS-GAL1TATA-HIS3 URA3::GAL4 17mers(x3)-CYC1TATA-LacZ*, [15]), which contains the two reporter genes *LacZ* and

HIS3, was used in the two-hybrid screening [4, 16]. Yeasts were first transformed, as described [38], with pBWRepA, a plasmid containing the entire WDV RepA open reading frame fused to the Gal4 DNA-binding domain (BD; *TRP1* marker) in the pGBT8 vector [46]. Then, they were transformed with the pGAD-GH (AD; *LEU2* marker) wheat cDNA library. The transformation mixture was plated on yeast drop-out selection media lacking tryptophan, leucine and histidine and supplemented with 5 mM and 10 mM 3-amino-1,2,4, triazole (3-AT; [5]) to reduce the appearance of false positive growing colonies. Transformants were routinely recovered during a 3 to 8 days period and were checked for growth in the presence of up to 20 mM 3-AT. To corroborate the interaction between the two fusion proteins, β -galactosidase activity was assayed by a replica filter assay as described [7]. Plasmid DNA was recovered from positive colonies by transforming into *E. coli* MH4, since this strain is *lenB*⁻, and its defect can be complemented by the *LEU2* gene present in the pGAD-GH plasmid. Deletions of GRAB1 were constructed using the *ApaI* (1-253), *Sall* (1-208), *SacI* (1-52) and *SacII* (80-287) restriction sites and deletions of GRAB2 using the *XhoI* (1-149), *BglII* (1-108), *Sall* (1-55) and *SmaI* (66-351) restriction sites.

Production of GST-fusion proteins and in vitro binding experiments

To produce the GST-GRAB fusion proteins, the oligonucleotide GRAB1-ATG (5'GGATCCATGGTGATGGCAGCGG) and T7 primer, and the oligonucleotides GRAB2-ATG (5'GGATCCATGGCGGACGTGACGGCGGTG) and T7 primer, were used to amplify the coding regions of GRAB1 and GRAB2, respectively by PCR. The products were then cloned in frame into the pGEX-KG vector. The GST-RepA was produced by cloning the WDV RepA ORF in frame into the pGEX-KG vector. *E. coli* BL21(DE3) transformants were grown to an OD₆₀₀ of 0.6 to 0.9 and then induced to express the fusion protein at 37 °C for 30 min by the addition of IPTG to 1 mM. GST fusion proteins were purified using glutathione-Sepharose beads (Pharmacia). Labeled

RepA protein was obtained by *in vitro* transcription and translation (IVT) using wheat germ extract (Promega), in the presence of ³⁵S-methionine, according to the manufacturer's conditions. Labeled GRAB1 and GRAB2 were produced by using TNT reticulocyte lysate (Promega) after cloning the same PCR products from GRAB1 and GRAB2 genes in plasmid pBluescriptKS and transcription using T7 RNA polymerase.

Plant cell culture

The *Triticum monococcum* suspension culture was obtained from P. Mullineaux (John Innes Center, UK) and maintained as described [46].

Inoculation of *N. benthamiana* plants

The PVX-derived pP2C2S vector [10] was used for transient expression of GRAB proteins in *N. benthamiana* plants. For GRAB1 constructions, a 1.1 Kb SmaI-XhoI fragment containing the complete GRAB1 cDNA was cloned into NruI/SalI digested pP2C2S vector to produce plasmid pP2-GRAB1. To construct a frame-shift GRAB1 mutant (GRAB1^{FS}), plasmid pP2-GRAB1 was partially digested with SacII and, then, religated after treatment with T4 DNA polymerase. For GRAB2 constructions, a 1.35 Kb SmaI-XhoI fragment containing the complete GRAB2 cDNA was cloned into NruI/SalI digested pP2C2S vector to produce plasmid pP2-GRAB2. To construct the frame-shift mutation (GRAB2^{FS}), plasmid pP2-GRAB2 was digested with BstEII and religated after treatment with Klenow. Infectious RNA was obtained by *in vitro* transcription of plasmid DNA digested with SpeI, using the T7 Cap Scribe kit (Boehringer Mannheim). RNA transcripts were diluted in 5 mM Na₃PO₄ (pH 7.0) and used to inoculate 3-week-old *N. benthamiana* plants (four in each case) using carborundum, as described [10, 17].

Transfection of wheat cultured cells by particle bombardment

Cells were pelleted by centrifugation at 1000 rpm for 3 minutes and the supernatant was removed. Approximately 0.20-0.25 ml of packed cells were spread with a spatula onto a Whatman #1 filter paper, which was placed on CHS medium supplemented with 0.25 M mannitol [30] and solidified with 0.8% agar (bombardment medium). Conditions for DNA adsorption and particle bombardment were as described [43, 46]. Overexpression of GRAB proteins in wheat cultured cells was carried out by cloning the coding regions in a plasmid [47] under the control of the CaMV 35S promoter. The 1.1 Kb EcoRI-XhoI fragment of GRAB1 and the 1.3 Kb EcoRI-ApaII fragment of GRAB2 were cloned into EcoRI/NdeI digested plasmid p35S.ZmRb1 [47] to produce p35S.GRAB1 and p35S.GRAB2. These plasmids contain the 3'-untranslated region of ZmRb1. Each experimental time point corresponds to a cell plate independently transfected. Experiments were repeated at least twice.

Analysis of WDV DNA replication

WDV DNA replication was analyzed essentially as described [43, 46]. Cells were ground in liquid nitrogen and DNA was isolated essentially as described [41] (Soni et al., 1994). After electrophoresis in 0.7% agarose gels, DNA was transferred to nylon membranes (Biodyne A) and detected by hybridization to probes labeled with digoxigenin-11-dUTP according to the conditions recommended by the manufacturer (DIG DNA labeling and detection kit, Boehringer Mannheim).

EXAMPLE 1

Isolation of cDNAs encoding GRAB proteins

Making use of the yeast two-hybrid approach (Fields and Song, 1989; Fields, 1993) a cDNA library was constructed from mRNA prepared from an actively growing wheat cell suspension culture. Screening was carried out using WDV RepA fused to the Gal4 DNA-binding domain. A significantly large number of cDNA clones allowed growth of co-transformants in selective (-his, +3AT) medium. Among those appeared during the first 6 days after transformation, those co-transformants showing a stronger

interaction, based on their ability to grow in the presence of ≥ 20 mM 3AT, and to produce an intense β -gal signal. Partial DNA sequence analysis revealed the existence of a group of 7 cDNA clones whose 5'-sequence was significantly related although they represented different clones as deduced by restriction analysis. Based on their ability to
5 interact with WDV RepA,) the proteins encoded by this group of cDNA clones were named GRAB proteins (Geminivirus RepA Binding). Two GRAB proteins, GRAB1 and GRAB2, are described herein.

Each cloned cDNA encoded protein which bound strongly to WDV RepA in yeasts. GRAB-1 and GRAB-2 cDNA clones were ~ 1.1 kbp long and each contained a
10 single open reading frame, including a putative ATG translation initiation site. The complete cDNA sequence and deduced amino acid sequence for the two GRAB proteins are shown in the sequence listing as SEQ ID Nos 9 to 12. The isolated clones contain the full-length coding region with the sequence around the first putative methionine showing a good consensus translation initiation sequence.

15 Amino acid analysis of GRAB1 and GRAB2 proteins revealed some striking features. First, the two proteins are totally unrelated in their C-terminal moieties although they appear to be highly related over a region spanning their ~ 170 N-terminal residues, where a significant degree of homology (58%) can be detected. Interestingly, the distribution of charged residues is not random. The unique C-terminal domain of
20 GRAB1 and GRAB2 contains 19% and 15%, respectively, of negatively charged residues (D, E) while their related N-terminal domain, which contains a high proportion of charged residues (30% and 33%, respectively), show a small bias in favour of positively charged amino acids (R, K, H, 18% and 20%, respectively).

In addition, northern analysis revealed the existence of mRNAs of the expected sizes each with the potential to encode GRAB1 and GRAB2, respectively. Both mRNAs were present in small amounts in wheat cultured cells and were even less abundant in differentiated cell types, i. e., roots and leaves.

5

Example 2.

N-terminus of GRAB proteins mediates binding to WDV RepA

To identify the region in the GRAB proteins involved in complex formation with WDV RepA, a series of deletions were constructed and analyzed for their ability to interact with the viral RepA protein in yeasts. Deletion of most (in GRAB1) or all (in GRAB2) the C-terminal domain did not reduce GRAB-RepA binding (Fig. 2). Even a truncated GRAB2 protein containing only its N-terminal 149 residues still retained a significant RepA binding ability (Fig. 2). On the contrary, a relatively small N-terminal deletion of GRAB1 (80 amino acids) or of GRAB2 (66 amino acids) totally abolished interaction (Fig. 2). Therefore, it is concluded that the N-terminal domain present in both proteins confers the capacity to form complexes with WDV RepA. Furthermore, the most N-terminal region of GRAB proteins appears to have the largest contribution to complex formation with WDV RepA.

20 Example 3.

C-terminal domain of WDV RepA mediates interaction with GRAB proteins

A similar deletion study was carried out to identify the sequences in the WDV RepA protein responsible for binding to GRAB proteins. As shown in Fig. 3, deletion of most of the N-terminal half of RepA (~ 150 residues) did not decrease its ability to

interact with GRAB proteins. However, elimination of just the C-terminal 37 amino acid residues of RepA completely destroyed binding to both GRAB1 and GRAB2 (Fig. 3), indicating that this small domain of RepA contains residues critical for binding. Interaction of GRAB with WDV Rep protein was also analysed, the other WDV early protein which is produced from the same mRNA encoding RepA but after a splicing event (Schalk et al., 1989). Thus, the 210 N-terminal residues of both RepA and Rep are identical, but the two viral proteins have distinct C-terminal domains. In agreement with the idea that the C-terminus of WDV RepA mediates binding to GRAB, WDV Rep was unable to form complexes with GRAB. These results together with data on the differential binding of WDV RepA and Rep to ZmRb1 (Xie et al., 1997) strongly suggest that RepA is a unique WDV protein likely involved in interfering with cellular physiology to create a cellular environment favorable to viral replication.

To confirm and extend the yeast two-hybrid interaction results, pull-down experiments were carried out to evaluate the interaction using purified proteins. After incubation of equal amounts of purified GST-RepA (0.2µg) with *in vitro* translated (IVT) GST-GRAB1 or GST-GRAB2, a fraction of the input ³⁵S-labeled GRAB proteins was recovered bound to glutathion-agarose beads (Fig. 4). Similar results were obtained using GST-GRAB1 and GST-GRAB2 and IVT WDV RepA protein (Fig. 4). Therefore, it was concluded that interaction between GRAB proteins and the geminiviral RepA can occur in the absence of other cellular proteins.

Example 4

Expression of GRAB mRNAs is restricted to a small number of cells in roots and embryos

To obtain some insight on the function that GRAB proteins may have in the cell, their expression pattern was analyzed by *in situ* hybridization. Northern analysis indicated that GRAB transcripts are not very abundant (see Fig. 1). The occurrence of GRAB mRNAs in root meristems appears to be restricted to a small number of cells. A similar patchy pattern was also observed of the histone H4 transcript, characteristic of S-phase cells. In particular, GRAB1 expression was restricted to some cells within the central cylinder and was virtually absent from cortical or epidermal cells. GRAB1 mRNA was also detected in some root cap initial cells. A comparable situation was found in developing embryos.

Altogether our analysis of the GRAB expression pattern under different growth conditions led us to conclude that both GRAB1 and GRAB2 mRNA levels increased as a response to changes in growth signals of, perhaps, a subset of cells within the culture and that they are largely dependent on nutrient availability. Furthermore, they reinforce the idea that GRAB proteins may serve different roles as part of an immediate early response, which may be a part of the transduction pathway connecting external signals to the regulation of cellular growth and/or differentiation.

A group of plant proteins is thus identified on the basis of their ability to form complexes with the RepA, the Rb-binding protein of WDV, a member of the plant geminiviridae family. Based on a database searching, we conclude that both GRAB1 and GRAB2 are not homologs to any known protein and, therefore, the cDNAs isolated encode previously unidentified proteins. However, this study revealed that they are related, in terms of primary sequence, throughout their N-terminal region. Using the amino acid sequence of GRAB1 or GRAB2, the output showed that these proteins possess a significant homology to several plant proteins of unknown function.

Interestingly, the homology was also restricted to the N-terminal first 150-170 residues, as initially observed for the group of GRAB proteins itself (Fig. 10A). Those shown in Fig. 10A correspond to otherwise apparently unrelated proteins. First, two Arabidopsis cDNA clones, ATAF1 and ATAF2, isolated by their ability to activate the 35S cauliflower mosaic virus (CAMV) promoter in yeasts (H. Hirt, personal communication). Second, the SENU5 CDNA, isolated in studies of leaf senescence in tomato (Genbank Acc. No.). Third, the NAM protein, the product of the Petunia *No Apical Meristem* (nam) gene, required for proper development of shoot apical meristems, which has been proposed to determine meristem location (Souer et al., 1996).

Example 5

Expression of GRAB 1 induces a necrotic phenotype

As a first step towards getting insight into the cellular roles of GRAB proteins we determined the effect of expressing either GRAB1 or GRAB2 in *N. benthamiana* plants. For this purpose, we made use of a potato virus X (PVX)-based expression vector, which ensures high levels of systemic expression at a given time and in the absence of chromosomal effects [6]. This system has been successfully used to analyze the effects of transiently expressed foreign proteins [18, 31, 32].

When *N. benthamiana* plants were inoculated with *in vitro* transcribed PVX RNA, the appearance of typical symptoms, clearly apparent at 10 days post inoculation (dpi), was indicative of efficient amplification of the PVX expression vector as compared with the mock-inoculated plants. Plants inoculated with the PVX-GRAB1 construct were already systemically infected by 12 dpi due to high level amplification of the GRAB1-expressing vector. This is confirmed by the level of PVX-GRAB1 RNA in the leaves, comparable to that of the wild type PVX-infected plants. Interestingly, all plants

expressing high levels of GRAB1 showed a tendency to develop, already at 12 dpi, a degenerative process, as revealed by the morphology of their older leaves. Furthermore, a prominent necrotic area appeared near the base of the aerial parts of the plant, especially at 28 dpi. At this stage, a significant reduction in the development of leaves and roots was also apparent. To determine whether the effects observed in whole plants were dependent on the expression of a full-length GRAB1 protein, we inoculated plants with a PVX construct that expressed GRAB1 mRNA carrying a frame-shift mutation close to the N-terminus. Thus, PVX-GRAB1^{Fs} bears a cDNA insert with a frame-shift mutation at amino acid position 78, which maintains the two most N-terminal conserved blocks (N1 and N2), and can produce a truncated protein of 159 residues. Expression of GRAB1^{Fs} did not produce any of the effects observed in plants expressing the full-length GRAB1 protein.

A similar study was carried out with the GRAB2 constructs. Plants infected with the PVX-GRAB2 construct showed delayed kinetics in the PVX vector amplification. This precluded high levels of GRAB2 expression at 12 dpi and plants had a morphology similar to that mock-inoculated plants. However, later after inoculation, the PVX vector accumulated at high levels. Interestingly, these GRAB2-expressing plants showed milder symptoms than plants infected with wild type PVX. None of them developed the degenerative process observed in GRAB1-expressing plants. We also tested the effect of expressing a truncated form of GRAB2. In this case, PVX-GRAB2^{Fs} produces a GRAB2 cDNA carrying a frame-shift mutation at amino acid position 33, thus producing a 50 amino acid-long truncated GRAB2 protein which conserved only the most N-terminal (N1) homology block. Plants inoculated with the PVX-GRAB2^{Fs} construct contain high levels of PVX and of GRAB^{Fs} RNAs. Taken together, the results of expressing the truncated forms of GRAB proteins, indicate that the induction of necrotic areas by GRAB1 and the delay in symptom appearance by GRAB2 are dependent upon

the expression of full-length proteins and strongly suggest that these specific effects may be mediated by the unique C-terminal domains of each GRAB1 and GRAB2 proteins.

The alignment shown in Fig. 4 revealed the existence of several amino acid motifs highly conserved among these related proteins. Thus, we noted the occurrence

5 of five motifs in the N-terminal domain (N1 to N5) which could correspond to blocks critical for their activity. Among them, the two most N-terminal motifs (N1 and N2) exhibit a net negative charge while the rest are positively charged. Based on our deletion analysis, all these motifs are required for efficient interaction with WDV RepA although N5 is not absolutely required and N1 seems to have a strong contribution (Fig.

10 3). The C-terminal domain, although unique in primary sequence to each protein in the family, shares the property of having a high net negative charge (15-20% of the residues are either D or E). This is particularly evident in both the GRAB proteins and the two ATAF members. The two GRAB proteins reported here, but in particular GRAB2, have a Q-rich domain in their C-terminal domains which could be involved in
15 transcriptional regulation as has been shown to be the case for other examples. In addition, a number of partial cDNA sequences derived from randomly sequenced EST from Arabidopsis and rice were also retrieved using the N-terminus of GRAB proteins as a query (not shown). Surprisingly, protein sequences from yeast or animal origins were not retrieved in this search.

20 One striking feature of this group of proteins is the large number of members with a related N-terminal domain that appears to be present in each species. For example, at least 5 members related to NAM (Souer et al., 1996) and 7 members related to GRAB (this work). Such an abundance poses the question of whether they actually have different functions. One possibility, already proposed for some NAM-related proteins is

that they have redundant functions in different locations of the plant during postembryonic development (Souer et al., 1996).

Regarding the consequences of GRAB overexpression on symptom appearance in PVX-infected plants, it is possible that both WDV and PVX share a, so far, unknown pathway affected by GRAB, although very different replication strategies are employed by these virus families. An alternative possibility is that GRAB overexpression may directly or indirectly trigger a general defense pathway or, simply, lead to a cellular environment which protect cells against different types of infection.

10 **Example 6.**

Overexpression of GRAB proteins in wheat cultured cells inhibits WDV DNA replication

To further investigate the possible function of the GRAB proteins isolated on the basis of their interaction with WDV RepA protein, we determined the effect of expressing GRAB proteins on geminiviral DNA replication. This assay has proven to be useful to evaluate the effect of plant Rb (ZmRb1) in viral DNA replication [47]. Thus, using a similar strategy, we co-transfected wheat cultured cells with combinations of the following plasmids: (i) one plasmid expressing either GRAB1 or GRAB2 under the control of the 35S CaMV promoter, which is active in the wheat cells used [47], (ii) a second plasmid expressing the WDV proteins required for efficient viral DNA replication (RepA and Rep) also under the control of the 35S CaMV promoter, and (iii) a third plasmid (pWori $\Delta\Delta$), a derivative of pWori [43, 46], used to monitor WDV DNA replication, which can replicate efficiently when the viral proteins are provided *in trans* [35, 47]. Expression of either GRAB1 or GRAB2 severely inhibited WDV DNA replication in cultured wheat cells, with GRAB2 exhibiting a stronger effect. These results indicate that WDV DNA replication is affected by GRAB proteins under cell culture conditions

REFERENCES

1. Accotto, G-P, Mullineaux, PM, Brown, SC, Marie, D: *Digitaria* streak geminivirus replicative forms are abundant in S-phase nuclei of infected cells. *Virology* 195: 257-259 (1993).
- 5 2. Aida, M, Ishida, T, Fukaki, H, Fujisawa, H, Tasaka, M.: Genes involved in organ separation in *Arabidopsis*: an analysis of the cup-shaped cotyledon mutant. *Plant Cell* 9: 841-857 (1997).
3. Angell, SM, Baulcombe, DC: Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA. *EMBO J.* 16: 3675-3684 (1997).
- 10 4. Bartel, PL, Chien, C-T, Sternglanz, R, Fields, S : Using the two-hybrid system to detect protein-protein interactions. In Hartley, D. A. (ed.), *Cellular Interactions in Development: a practical approach*. Oxford University Press, Oxford, UK, pp. 153-179 (1993a).
5. Bartel, PL, Chien, C-T, Sternglanz, R, Fields, S: Elimination of false positives that
15 arise in using the two-hybrid system. *BioTechniques* 14: 920-924 (1993b).
6. Baulcombe, DC., Chapman, S, Santa Cruz, S: Jellyfish green fluorescent protein as a reporter for virus infections. *Plant J.* 7: 1045-1053 (1995).
7. Breeden, L, Nasmyth, K: Regulation of the yeast HO gene. *Cold Spring Harbor Symp. Quant. Biol.* 50: 643-650 (1985).
- 20 8. Coen, ES., Meyerowitz, EM: The war of whorls: genetic interactions controlling flower developmen. *Nature* 353: 31-37 (1991).
9. Courey, AJ, Tjian, R: Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. *Cell* 55: 887-898 (1988).
10. Chapman, S, Kavanagh, TA, Baulcombe, DC: Potato virus X as a vector for gene
25 expression in plants. *Plant J.* 2: 549-557 (1992).
11. Davies, JW, Stanley, J: Geminivirus genes and vectors. *Trends Genet.* 5: 77-81 (1989).

12. Doerner, P, Jørgensen, J, You, R, Steppuhn, J, Lamb, C: Control of root growth and development by cyclin expression. *Nature* 380: 520-523 (1996).
13. Eagle, PA, Orozco, BM, Hanley-Bowdoin, L: A DNA sequence required for geminivirus replication also mediates transcriptional regulation. *Plant Cell* 6: 1157-1170 (1994).
14. Fanning, E, and Knippers, R: Structure and function of simian virus 40 large tumor antigen. *Annu. Rev. Biochem.* 61: 55-85 (1992).
15. Feilotter, HE, Hannon, GJ, Ruddell, CJ, Beach, D: Construction of an improved host strain for two-hybrid screening. *Nucleic Acids Res.* 22: 1502-1503 (1994).
- 10 16. Fields, S, Song, O: A novel genetic system to detect protein-protein interactions. *Nature* 340: 245-246 (1989).
17. Guo, HS, Garcia, JA: Delayed resistance to plum pox potyvirus mediated by a mutated RNA replicase gene: involvement of a gene-silencing mechanism. *Mol. Plant-Microbe Inter.* 10: 160-170 (1997).
- 15 18. Hammond-Kosack, KE, Staskawicz, BJ, Jones, JDG, Baulcombe, DC: Functional expression of a fungal avirulence gene from a modified potato virus X genome. *Mol Plant-Microbe Interact.* 8: 181-185 (1995).
19. Hassel, JA, Brinton, BT: SV40 and polyomavirus DNA replication. In DePamphilis, M. L. (ed.). *DNA replication in eukaryotic cells*. Cold Spring Harbor Laboratory Press, New York, pp. 639-677 (1996).
- 20 20. Jacobs, T: Control of the cell cycle. *Dev. Biol.* 153: 1-15 (1992).
21. Jansen-Durr, P: How viral oncogenes make the cell cycle. *Trends Genet.* 12: 270-275 (1996).
22. John, I, Hackett, R, Cooper, W, Drake, R, Farrell, A, Grierson, D: Cloning and characterization of tomato leaf senescence-related cDNAs. *Plant Mol. Biol.* 33: 641-651 (1997).
- 25

23. Kozak, M: At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. *J. Mol. Biol.* 196: 947-950 (1987).
24. Lazarowitz, S: Geminiviruses: genome structure and gene function. *Crit. Rev. Plant Sci.* 11: 327-349 (1992).
- 5 25. Long, JA, Moan, EI, Medford, JI, Barton, MK: A member of the KNOTTED class of homeodomain proteins encoded by the STM gene of Arabidopsis. *Nature* 379: 66-69 (1996)
26. Ludlow, JW: Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. *FASEB J.* 7: 866-871 (1993).
- 10 27. Martin, C, Paz-Ares, J: MYB transcription factors in plants. *Trends Genet.* 13: 67-73 (1997)
28. Moran, E: Interaction of adenoviral proteins with pRB and p53. *FASEB J.* 7: 880-885 (1993).
29. Nagar, S, Pedersen, TJ, Carrick, KM, Hanley-Bowdoin, L, Robertson, D: A
15 geminivirus induces expression of a host DNA synthesis protein in terminally differentiated plant cells. *Plant Cell* 7: 705-719 (1995)
30. Perl, A, Kless, H, Blumenthal, A, Galili, G, Galun, E: Improvement of plant regeneration and GUS expression in scutellar wheat calli by optimization of culture conditions and DNA-microprojectile delivery procedures. *Mol. Gen. Genet.* 235:
20 279-284 (1992).
31. Ratcliff, F, Harrison, BD, Baulcombe, DC: A similarity between viral defense and gene silencing in plants. *Science* 276: 1558-1560 (1997).
32. Rommens, CMT, Salmeron, JM, Baulcombe, DC, Staskawicz, BJ: Use of a gene expression system based on potato virus X to rapidly identify and characterize a
25 tomato pto homolog that controls fenthion sensitivity. *Plant Cell* 7: 249-257 (1995).

33. Sablowski, RWM, Meyerowitz, EM: A homolog of *NO APICAL MERISTEM* is an immediate target of the floral homeotic genes *APETALA3/PISTILLATA*. *Cell* 92: 93-103 (1998).
34. Sambrook, J, Fritsch, EF, Maniatis, T: Molecular cloning: A laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, (1989).
35. Sanz-Burgos, AP, Gutierrez, C: Organization of the *cis*-acting element required for wheat dwarf geminivirus DNA replication and visualization of a Rep protein-DNA complex. *Virology* (1998, in press).
36. Saraste, M, Sibbald, PR, Wittinghofer, A: The P-loop — a common motif in ATP- and GTP-binding proteins. *Trends Biochem. Sci.* 15: 430-434 (1990).
37. Schalk, H-J, Matzeit, V, Schiller, B, Schell, J, Gronenborn, B: Wheat dwarf virus, a geminivirus of graminaceous plants needs splicing for replication. *EMBO J.* 8: 359-364 (1989).
38. Schiestl, RH, Gietz, D: High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. *Curr. Genet.* 16: 339-346 (1989).
39. Shaul, O, van Montagu, M, Inzé, D: Regulation of cell division in Arabidopsis. *Crit. Rev. Plant. Sci.* 15: 97-112 (1996).
40. Shore, P, Sharrocks, AD: The MADS-box family of transcription factors. *Eur. J. Biochem.* 229: 1-13 (1995).
41. Soni, R, Murray, JAH: Isolation of intact DNA and RNA from plant tissues. *Anal Biochem.* 218: 474-476 (1994).
42. Souer, E, van Houwelingen, A, Kloos, D, Mol, J, Koes, R: The No Apical Meristem gene of Petunia is required for pattern formation in embryos and flowers and is expressed at meristem and primordia boundaries. *Cell* 85: 159-170 (1996).
43. Suárez-López, P, Gutiérrez, C: DNA replication of wheat dwarf geminivirus vectors: effects of origin structure and size. *Virology* 227: 389-399 (1997).

44. Van der Krol, AR, Chua, N-H: Flower development in petunia. *Plant Cell* 5: 1195-1203 (1993).
45. Vousden, K: Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. *FASEB J.* 7: 872-879 (1993).
- 5 46. Xie, Q, Suárez-López, P, Gutiérrez, C: Identification and analysis of a retinoblastoma binding motif in the replication protein of a plant DNA virus: requirement for efficient viral DNA replication. *EMBO J.* 14: 4073-4082 (1995).
47. Xie, Q, Sanz-Burgos, AP, Hannon, GJ, Gutierrez, C: Plant cells contain a novel member of the retinoblastoma family of growth regulatory proteins. *EMBO J.* 15: 4900-4908 (1996).
- 10

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: CONSEJO SUPERIOR DE INVESTIGACIONES
CIENTIFICAS

(B) STREET: SERRANO, 113

(C) CITY: MADRID

(E) COUNTRY: SPAIN

(F) POSTAL CODE (ZIP): 28006

(A) NAME: CRISANTO GUTIERREZ-ARMENTA

(B) STREET: CENTRO DE BIOLOGIA MOLECULAR, CSIC-UAM

(C) CITY: MADRID

(E) COUNTRY: SPAIN

(F) POSTAL CODE (ZIP): 28049

(A) NAME: QI XIE

(B) STREET: CENTRO DE BIOLOGIA MOLECULAR, CSIC-UAM

(C) CITY: MADRID

(E) COUNTRY: SPAIN

(F) POSTAL CODE (ZIP): 28049

(A) NAME: ANDRES SANZ-BURGOS

(B) STREET: CENTRO DE BIOLOGIA MOLECULAR, CSIC-UAM

(C) CITY: MADRID

(E) COUNTRY: SPAIN

(F) POSTAL CODE (ZIP): 28049

(ii) TITLE OF INVENTION: PLANT GRAB PROTEINS

(iii) NUMBER OF SEQUENCES: 12

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: ES 9701292

(B) FILING DATE: 12-JUN-1997

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 459 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Triticum monococcum*

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..459

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTGCCGNNNG GGTTCGGTT CCACCCGACG GACGAGGAGN NNNNNNNNNN NTACCTCNNN
60

NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNATCN NNNNNNNNNN NNNNNNNNNN
120

NNNNNNCCGT GGNNNCTCCC GNNNNNNNNN NNNNNNNNNN NNNNNGAGTG GTACTTCTTC
180

NNNNNNNNNN NNNNNAAGTA CCCCNNGGC NNNGCENNA ACCGGNNNNN NNNNNNNGGC
240

TACTGGAAGG CCACCGGCNN NGACNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNGGGNNN
300

AAGAAGNNNC TCGTCTTCTA CNNGGCNNN NNNNNNNNG GGNNNNNNN NNNNTGGNNN
360

ATGCACGAGT ACCGCCTCEN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
420

NNNNNNNNNN NNTGGNNNNN NNNGCENNN NNNNNNAAG
459

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 462 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Triticum monococcum*

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..462

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CTTCCANNNG GGTTCGGTT CCACCCACC GACGAGGAGN NNNNNNNNNN NTACCTCNNN
60

NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNATCN NNNNNNNNNN NNNNNNNNNN
120

NNNNNNCCGT GGNNNCTCCC GNNNNNNNNN NNNNNNNNNN NNNNNGAGTG GTTCTTCTTC
180

NNNNNNNNNN NNNNNAAGTA CCCGNNNGGG NNNCGCNNNA ACCGGNNNNN NNNNNNNGGG
240

TACTGGAAGG CGACGGGGNN NGACNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
300

NNNNNNGGCN NNAAGAAGNN NCTCGTCTTT TACNNNGGCN NNNNNNNNNN NGGCNNNNNN
360

NNNNNTGGN NNATGCACGA GTACGCCTC NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
420

NNNNNNNNNN NNNNTGGNN NNNNNNNCGG NNNNNNNNNA AA
462

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 153 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Triticum monococcum*

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..459

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Leu Pro Xaa Gly Phe Arg Phe His Pro Thr Asp Glu Glu Xaa Xaa Xaa
1 5 10 15

Xaa Tyr Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Trp Xaa Leu Pro Xaa
 35 40 45
 5 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu Trp Tyr Phe Phe Xaa Xaa Xaa Xaa
 50 55 60
 Xaa Lys Tyr Pro Xaa Gly Xaa Arg Xaa Asn Arg Xaa Xaa Xaa Xaa Gly
 65 70 75 80
 10 Tyr Trp Lys Ala Thr Gly Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 85 90 95
 Xaa Xaa Gly Xaa Lys Lys Xaa Leu Val Phe Tyr Xaa Gly Xaa Xaa Xaa
 100 105 110
 15 Xaa Gly Xaa Xaa Xaa Xaa Trp Xaa Met His Glu Tyr Arg Leu Xaa Xaa
 115 120 125
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 130 135 140
 20 Trp Xaa Xaa Xaa Arg Xaa Xaa Xaa Lys
 145 150

25 (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 154 amino acids
 (B) TYPE: amino acid
 30 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 35 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: internal
 40 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Triticum monococcum*

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Leu Pro Xaa Gly Phe Arg Phe His Pro Thr Asp Glu Glu Xaa Xaa Xaa
 1 5 10 15
 50 Xaa Tyr Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30
 55 Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Trp Xaa Leu Pro Xaa
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu Trp Phe Phe Phe Xaa Xaa Xaa Xaa
 50 55 60

Xaa Lys Tyr Pro Xaa Gly Xaa Arg Xaa Asn Arg Xaa Xaa Xaa Xaa Gly
 65 70 75 80
 5 Tyr Trp Lys Ala Thr Gly Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 85 90 95
 Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Lys Lys Xaa Leu Val Phe Tyr Xaa
 100 105 110
 10 Gly Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Trp Xaa Met His Glu Tyr
 115 120 125
 Arg Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 130 135 140
 15 Xaa Trp Xaa Xaa Xaa Arg Xaa Xaa Xaa Lys
 145 150

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 459 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 25
 (ii) MOLECULE TYPE: cDNA
 30
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (vi) ORIGINAL SOURCE:
 35 (A) ORGANISM: Triticum monococcum
 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..459
 40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CTG CCG CCG GGG TTC CGG TTC CAC CCG ACG GAC GAG GAG CTG GTG GCG
 45 48
 Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Leu Val Ala
 1 5 10 15
 GAC TAC CTC TGC GCG CGC GCG GCC GGC CGC GCG CCG CCG GTG CCC ATC
 50 96
 Asp Tyr Leu Cys Ala Arg Ala Ala Gly Arg Ala Pro Pro Val Pro Ile
 20 25 30
 ATC GCC GAG CTC GAC CTC TAC CGG TTC GAC CCG TGG GAG CTC CCG GAG
 55 144
 Ile Ala Glu Leu Asp Leu Tyr Arg Phe Asp Pro Trp Glu Leu Pro Glu
 35 40 45

CGG GCG CTC TTC GGG GCG CGG GAG TGG TAC TTC TTC ACG CCG CGG GAC
192
Arg Ala Leu Phe Gly Ala Arg Glu Trp Tyr Phe Phe Thr Pro Arg Asp
50 55 60

5 CGC AAG TAC CCC AAC GGC TCC CGC CCC AAC CGG GCC GCC GGG GGC GGC
240
Arg Lys Tyr Pro Asn Gly Ser Arg Pro Asn Arg Ala Ala Gly Gly Gly
65 70 75 80

10 TAC TGG AAG GCC ACC GGC GCC GAC AGG CCC GTG GCG CGC GCG GGC AGG
288
Tyr Trp Lys Ala Thr Gly Ala Asp Arg Pro Val Ala Arg Ala Gly Arg
85 90 95

15 ACC GTC GGG ATC AAG AAG GCG CTC GTC TTC TAC CAC GGC AGG CCG TCG
336
Thr Val Gly Ile Lys Lys Ala Leu Val Phe Tyr His Gly Arg Pro Ser
100 105 110

20 GCG GGG GTC AAG ACG GAC TGG ATC ATG CAC GAG TAC CGC CTC GCC GGC
384
Ala Gly Val Lys Thr Asp Trp Ile Met His Glu Tyr Arg Leu Ala Gly
115 120 125

25 GCC GAC GGA CGC GCC GCC AAG AAC GGC GGC ACG CTC AGG CTT GAC GAA
432
Ala Asp Gly Arg Ala Ala Lys Asn Gly Gly Thr Leu Arg Leu Asp Glu
130 135 140

30 TGG GTG CTC TGC CGC CTA TAC AAC AAG
459
Trp Val Leu Cys Arg Leu Tyr Asn Lys
145 150

35

(2) INFORMATION FOR SEQ ID NO: 6:

- 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 153 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- 45 (ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Leu Val Ala
1 5 10 15

50 Asp Tyr Leu Cys Ala Arg Ala Ala Gly Arg Ala Pro Pro Val Pro Ile
20 25 30

Ile Ala Glu Leu Asp Leu Tyr Arg Phe Asp Pro Trp Glu Leu Pro Glu
35 40 45

55 Arg Ala Leu Phe Gly Ala Arg Glu Trp Tyr Phe Phe Thr Pro Arg Asp
50 55 60

Arg Lys Tyr Pro Asn Gly Ser Arg Pro Asn Arg Ala Ala Gly Gly Gly
65 70 75 80

5 Tyr Trp Lys Ala Thr Gly Ala Asp Arg Pro Val Ala Arg Ala Gly Arg
85 90 95

Thr Val Gly Ile Lys Lys Ala Leu Val Phe Tyr His Gly Arg Pro Ser
100 105 110

10 Ala Gly Val Lys Thr Asp Trp Ile Met His Glu Tyr Arg Leu Ala Gly
115 120 125

Ala Asp Gly Arg Ala Ala Lys Asn Gly Gly Thr Leu Arg Leu Asp Glu
130 135 140

15 Trp Val Leu Cys Arg Leu Tyr Asn Lys
145 150

20 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 462 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

35 (A) ORGANISM: Triticum monococcum

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..462

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CTT CCA CCG GGG TTC CGG TTC CAC CCC ACC GAC GAG GAG GTG GTC ACC
48

45 Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Val Val Thr
155 160 165

CAC TAC CTC ACC CGC AAG GTC CTC CGC GAA TCC TTC TCC TGC CAA GTG
96

50 His Tyr Leu Thr Arg Lys Val Leu Arg Glu Ser Phe Ser Cys Gln Val
170 175 180 185

ATC ACC GAC GTC GAC CTC AAC AAG AAC GAG CCG TGG GAG CTC CCG GGC
144

55 Ile Thr Asp Val Asp Leu Asn Lys Asn Glu Pro Trp Glu Leu Pro Gly
190 195 200

CTC GCG AAG ATG GGC GAG AAG GAG TGG TTC TTC TTC GCG CAC AAG GGT
192

Leu Ala Lys Met Gly Glu Lys Glu Trp Phe Phe Phe Ala His Lys Gly
205 210 215

5

CGG AAG TAC CCG ACG GGG ACG CGC ACC AAC CGG GCG ACG AAG AAG GGG
240

Arg Lys Tyr Pro Thr Gly Thr Arg Thr Asn Arg Ala Thr Lys Lys Gly
220 225 230

10

TAC TGG AAG GCG ACG GGG AAG GAC AAG GAG ATC TTC CGC GGC AAG GGC
288

Tyr Trp Lys Ala Thr Gly Lys Asp Lys Glu Ile Phe Arg Gly Lys Gly
235 240 245

15

CGG GAC GCC GTC CTT GTC GGC ATG AAG AAG ACG CTC GTC TTT TAC ACC
336

Arg Asp Ala Val Leu Val Gly Met Lys Lys Thr Leu Val Phe Tyr Thr
250 255 260 265

20

GGC CGC GCC CCC AGC GGC GGG AAG ACG CCG TGG GTG ATG CAC GAG TAC
384

Gly Arg Ala Pro Ser Gly Gly Lys Thr Pro Trp Val Met His Glu Tyr
270 275 280

25

CGC CTC GAG GGC GAG CTG CCC CAT CGC CTT CCC CGC ACC GCC AAG GAC
432

Arg Leu Glu Gly Glu Leu Pro His Arg Leu Pro Arg Thr Ala Lys Asp
285 290 295

30

GAT TGG GCT GTT TGC CGG GTG TTC AAC AAA
462

Asp Trp Ala Val Cys Arg Val Phe Asn Lys
300 305

35

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 154 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Val Val Thr
1 5 10 15

50

His Tyr Leu Thr Arg Lys Val Leu Arg Glu Ser Phe Ser Cys Gln Val
20 25 30

Ile Thr Asp Val Asp Leu Asn Lys Asn Glu Pro Trp Glu Leu Pro Gly
35 40 45

55

Leu Ala Lys Met Gly Glu Lys Glu Trp Phe Phe Phe Ala His Lys Gly
50 55 60

Arg Lys Tyr Pro Thr Gly Thr Arg Thr Asn Arg Ala Thr Lys Lys Gly
 65 70 75 80
 Tyr Trp Lys Ala Thr Gly Lys Asp Lys Glu Ile Phe Arg Gly Lys Gly
 5 85 90 95
 Arg Asp Ala Val Leu Val Gly Met Lys Lys Thr Leu Val Phe Tyr Thr
 100 105 110
 Gly Arg Ala Pro Ser Gly Gly Lys Thr Pro Trp Val Met His Glu Tyr
 10 115 120 125
 Arg Leu Glu Gly Glu Leu Pro His Arg Leu Pro Arg Thr Ala Lys Asp
 130 135 140
 Asp Trp Ala Val Cys Arg Val Phe Asn Lys
 145 150

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1090 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Triticum monococcum*

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 94..954

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AATTCGGCAC GAGACAGTCC ACCACGCACG TGCAGCAGCA CCAGCGCCCG AGAATCCCAT
60

TCCCATCGAC GGAGAAGAAG AAGTGAAGAA ACA ATG GTG ATG GCA GCG GCG GAG
114

Met Val Met Ala Ala Ala Glu
155 160

CGG CGG GAC GCG GAG GCG GAG CTG AAC CTG CCG CCG GGG TTC CGG TTC
162

Arg Arg Asp Ala Glu Ala Glu Leu Asn Leu Pro Pro Gly Phe Arg Phe
165 170 175

CAC CCG ACG GAC GAG GAG CTG GTG GCG GAC TAC CTC TGC GCG GCG GCG
210

His Pro Thr Asp Glu Glu Leu Val Ala Asp Tyr Leu Cys Ala Arg Ala

	180	185	190
	GCC GGC CGC GCG CCG CCG GTG CCC ATC ATC GCC GAG CTC GAC CTC TAC		
	258		
5	Ala Gly Arg Ala Pro Pro Val Pro Ile Ile Ala Glu Leu Asp Leu Tyr		
	195	200	205
	CGG TTC GAC CCG TGG GAG CTC CCG GAG CGG GCG CTC TTC GGG GCG CGG		
	306		
10	Arg Phe Asp Pro Trp Glu Leu Pro Glu Arg Ala Leu Phe Gly Ala Arg		
	210	215	220 225
	GAG TGG TAC TTC TTC ACG CCG CGG GAC CGC AAG TAC CCC AAC GGC TCC		
	354		
15	Glu Trp Tyr Phe Phe Thr Pro Arg Asp Arg Lys Tyr Pro Asn Gly Ser		
		230	235 240
	CGC CCC AAC CGG GCC GCC GGG GGC GGC TAC TGG AAG GCC ACC GGC GCC		
	402		
20	Arg Pro Asn Arg Ala Ala Gly Gly Gly Tyr Trp Lys Ala Thr Gly Ala		
		245	250 255
	GAC AGG CCC GTG GCG CGC GCG GGC AGG ACC GTC GGG ATC AAG AAG GCG		
	450		
25	Asp Arg Pro Val Ala Arg Ala Gly Arg Thr Val Gly Ile Lys Lys Ala		
		260	265 270
	CTC GTC TTC TAC CAC GGC AGG CCG TCG GCG GGG GTC AAG ACG GAC TGG		
	498		
30	Leu Val Phe Tyr His Gly Arg Pro Ser Ala Gly Val Lys Thr Asp Trp		
		275	280 285
	ATC ATG CAC GAG TAC CGC CTC GCC GGC GCC GAC GGA CGC GCC GCC AAG		
	546		
35	Ile Met His Glu Tyr Arg Leu Ala Gly Ala Asp Gly Arg Ala Ala Lys		
	290	295	300 305
	AAC GGC GGC ACG CTC AGG CTT GAC GAA TGG GTG CTC TGC CGC CTA TAC		
	594		
40	Asn Gly Gly Thr Leu Arg Leu Asp Glu Trp Val Leu Cys Arg Leu Tyr		
		310	315 320
	AAC AAG AAG AAC CAG TGG GAG AAG ATG CAG CGG CAG CGG CAG GAG GAG		
	642		
45	Asn Lys Lys Asn Gln Trp Glu Lys Met Gln Arg Gln Arg Gln Glu Glu		
		325	330 335
	GAG GCG GCG GCC AAG GCT GCG GCG TCA CAG TCG GTC TCC TGG GGT GAG		
	690		
50	Glu Ala Ala Ala Lys Ala Ala Ala Ser Gln Ser Val Ser Trp Gly Glu		
		340	345 350
	ACG CGG ACG CCG GAG TCC GAC GTC GAC AAC GAT CCG TTC CCG GAG CTG		
	738		
55	Thr Arg Thr Pro Glu Ser Asp Val Asp Asn Asp Pro Phe Pro Glu Leu		
		355	360 365

5 GAC TCG CTG CCG GAG TTC CAG ACG GCA AAC GCG TCA ATA CTG CCC AAG
 786
 Asp Ser Leu Pro Glu Phe Gln Thr Ala Asn Ala Ser Ile Leu Pro Lys
 370 375 380 385
 10 GAG GAG GTG CAG GAG CTG GGC AAC GAC GAC TGG CTC ATG GGG ATC AGC
 834
 Glu Glu Val Gln Glu Leu Gly Asn Asp Asp Trp Leu Met Gly Ile Ser
 390 395 400
 15 CTC GAC GAC CTG CAG GGC CCC GGC TCC CTG ATG CTG CCC TGG GAC GAC
 882
 Leu Asp Asp Leu Gln Gly Pro Gly Ser Leu Met Leu Pro Trp Asp Asp
 405 410 415
 20 TCC TAC GCC GCC TCG TTC CTG TCG CCG GTG GCC ACG ATG AAG ATG GAG
 930
 Ser Tyr Ala Ala Ser Phe Leu Ser Pro Val Ala Thr Met Lys Met Glu
 420 425 430
 25 CAG GAC GTC AGC CCA TTC TTC TTC TGAGCTCTCA ATACTCTCAC GGTCGCACTG
 984
 Gln Asp Val Ser Pro Phe Phe Phe
 435 440
 30 TTGTGTGCGG CGTAACTGTA GATAGTTCAC ATTTGTTCAG GATTTATTTG TAACGTTGCT
 1044
 TCTTTTATAC GATACTCTCT TCCTTTCTAA AAAAAAAAAA AAAAAA
 1090

(2) INFORMATION FOR SEQ ID NO: 10:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 287 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 40 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

45 Met Val Met Ala Ala Ala Glu Arg Arg Asp Ala Glu Ala Glu Leu Asn
 1 5 10 15
 Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Leu Val Ala
 20 25 30
 50 Asp Tyr Leu Cys Ala Arg Ala Ala Gly Arg Ala Pro Pro Val Pro Ile
 35 40 45
 Ile Ala Glu Leu Asp Leu Tyr Arg Phe Asp Pro Trp Glu Leu Pro Glu
 50 55 60
 55 Arg Ala Leu Phe Gly Ala Arg Glu Trp Tyr Phe Phe Thr Pro Arg Asp
 65 70 75 80
 Arg Lys Tyr Pro Asn Gly Ser Arg Pro Asn Arg Ala Ala Gly Gly Gly

	85	90	95
	Tyr Trp Lys Ala Thr Gly Ala Asp Arg Pro Val Ala Arg Ala Gly Arg		
	100	105	110
5	Thr Val Gly Ile Lys Lys Ala Leu Val Phe Tyr His Gly Arg Pro Ser		
	115	120	125
10	Ala Gly Val Lys Thr Asp Trp Ile Met His Glu Tyr Arg Leu Ala Gly		
	130	135	140
	Ala Asp Gly Arg Ala Ala Lys Asn Gly Gly Thr Leu Arg Leu Asp Glu		
	145	150	155
15	Trp Val Leu Cys Arg Leu Tyr Asn Lys Lys Asn Gln Trp Glu Lys Met		
	165	170	175
	Gln Arg Gln Arg Gln Glu Glu Glu Ala Ala Ala Lys Ala Ala Ala Ser		
	180	185	190
20	Gln Ser Val Ser Trp Gly Glu Thr Arg Thr Pro Glu Ser Asp Val Asp		
	195	200	205
	Asn Asp Pro Phe Pro Glu Leu Asp Ser Leu Pro Glu Phe Gln Thr Ala		
25	210	215	220
	Asn Ala Ser Ile Leu Pro Lys Glu Glu Val Gln Glu Leu Gly Asn Asp		
	225	230	235
30	Asp Trp Leu Met Gly Ile Ser Leu Asp Asp Leu Gln Gly Pro Gly Ser		
	245	250	255
	Leu Met Leu Pro Trp Asp Asp Ser Tyr Ala Ala Ser Phe Leu Ser Pro		
	260	265	270
35	Val Ala Thr Met Lys Met Glu Gln Asp Val Ser Pro Phe Phe Phe		
	275	280	285

(2) INFORMATION FOR SEQ ID NO: 11:

- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1295 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - 45 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- 50 (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
- (A) ORGANISM: Triticum monococcum
- 55 (ix) FEATURE:
- (A) NAME/KEY: CDS
 - (B) LOCATION: 109..1161

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

5 ATTCGGCACG AGATCACCTC TAACATCTCG ATCTACCTCT TCCTCCTCCT CAGCTCTCGT
 60
 TCCATCAGGT TCTTCCACAG CGTAGCAAGG CAATCTAGTA GATCCTCC ATG TCG GAC
 117
 10 Met Ser Asp
 290
 GTG ACG GCG GTG ATG GAT CTG GAG GTG GAG GAG CCG CAG CTG GCG CTT
 165
 15 Val Thr Ala Val Met Asp Leu Glu Val Glu Glu Pro Gln Leu Ala Leu
 295 300 305
 CCA CCG GGG TTC CGG TTC CAC CCC ACC GAC GAG GAG GTG GTC ACC CAC
 213
 20 Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Val Val Thr His
 310 315 320
 TAC CTC ACC CGC AAG GTC CTC CGC GAA TCC TTC TCC TGC CAA GTG ATC
 261
 25 Tyr Leu Thr Arg Lys Val Leu Arg Glu Ser Phe Ser Cys Gln Val Ile
 325 330 335
 ACC GAC GTC GAC CTC AAC AAG AAC GAG CCG TGG GAG CTC CCG GGC CTC
 309
 30 Thr Asp Val Asp Leu Asn Lys Asn Glu Pro Trp Glu Leu Pro Gly Leu
 340 345 350
 GCG AAG ATG GGC GAG AAG GAG TGG TTC TTC TTC GCG CAC AAG GGT CGG
 357
 35 Ala Lys Met Gly Glu Lys Glu Trp Phe Phe Phe Ala His Lys Gly Arg
 355 360 365 370
 AAG TAC CCG ACG GGG ACG CGC ACC AAC CGG GCG ACG AAG AAG GGG TAC
 405
 40 Lys Tyr Pro Thr Gly Thr Arg Thr Asn Arg Ala Thr Lys Lys Gly Tyr
 375 380 385
 TGG AAG GCG ACG GGG AAG GAC AAG GAG ATC TTC CGC GGC AAG GGC CGG
 453
 45 Trp Lys Ala Thr Gly Lys Asp Lys Glu Ile Phe Arg Gly Lys Gly Arg
 390 395 400
 GAC GCC GTC CTT GTC GGC ATG AAG AAG ACG CTC GTC TTT TAC ACC GGC
 501
 50 Asp Ala Val Leu Val Gly Met Lys Lys Thr Leu Val Phe Tyr Thr Gly
 405 410 415
 CGC GCC CCC AGC GGC GGG AAG ACG CCG TGG GTG ATG CAC GAG TAC CGC
 549
 55 Arg Ala Pro Ser Gly Gly Lys Thr Pro Trp Val Met His Glu Tyr Arg
 420 425 430

CTC GAG GGC GAG CTG CCC CAT CGC CTT CCC CGC ACC GCC AAG GAC GAT
 597
 Leu Glu Gly Glu Leu Pro His Arg Leu Pro Arg Thr Ala Lys Asp Asp
 435 440 445 450
 5
 TGG GCT GTT TGC CGG GTG TTC AAC AAA GAC TTG GCG GCG AGG AAT GCG
 645
 Trp Ala Val Cys Arg Val Phe Asn Lys Asp Leu Ala Ala Arg Asn Ala
 455 460 465
 10
 CCC CAG ATG GCG CCG GCG GCC GAC GGT GGC ATG GAG GAC CCG CTC GCC
 693
 Pro Gln Met Ala Pro Ala Ala Asp Gly Gly Met Glu Asp Pro Leu Ala
 470 475 480
 15
 TTC CTC GAT GAC TTG CTC ATC GAC ACC GAC CTG TTC GAC GAC GCG GAC
 741
 Phe Leu Asp Asp Leu Leu Ile Asp Thr Asp Leu Phe Asp Asp Ala Asp
 485 490 495
 20
 CTG CCG ATG CTC ATG GAC TCT CCG TCT GGC GCT GAC GAC TTC GCC GGC
 789
 Leu Pro Met Leu Met Asp Ser Pro Ser Gly Ala Asp Asp Phe Ala Gly
 500 505 510
 25
 GCT TCG AGC TCC ACC TGC AGC GCG GCC CTG CCG CTT GAG CCG GAC GCG
 837
 Ala Ser Ser Ser Thr Cys Ser Ala Ala Leu Pro Leu Glu Pro Asp Ala
 515 520 525 530
 30
 GAG CTA CCG GTG CTG CAT CCG CAG CAG CAG CAG AGC CCC AAC TAC TTC
 885
 Glu Leu Pro Val Leu His Pro Gln Gln Gln Gln Ser Pro Asn Tyr Phe
 535 540 545
 35
 TTC ATG CCG GCG ACG GCC AAC GGC AAT CTT GGC GGC GCC GAG TAC TCA
 933
 Phe Met Pro Ala Thr Ala Asn Gly Asn Leu Gly Gly Ala Glu Tyr Ser
 550 555 560
 40
 CCC TAC CAG GCT ATG GGG GAC CAG CAG GCC GCG ATC CGC AGG TAC TGC
 981
 Pro Tyr Gln Ala Met Gly Asp Gln Gln Ala Ala Ile Arg Arg Tyr Cys
 565 570 575
 45
 AAG CCG AAG GCG GAG GTA GCG TCT TCG TCG GCG CTG CTG AGC CCT TCG
 1029
 Lys Pro Lys Ala Glu Val Ala Ser Ser Ser Ala Leu Leu Ser Pro Ser
 580 585 590
 50
 CTG GGC TTG GAC ACG GCG GCG CTT GCC GGC GCG GAG ACC TCC TTC CTG
 1077
 Leu Gly Leu Asp Thr Ala Ala Leu Ala Gly Ala Glu Thr Ser Phe Leu
 595 600 605 610
 55
 ATG CCG TCA TCG CGG TCG TAC CTC GAT CTG GAG GAG CTG TTC CGG GGC
 1125
 Met Pro Ser Ser Arg Ser Tyr Leu Asp Leu Glu Glu Leu Phe Arg Gly

615

620

625

GAG CCT CTC ATG GAC TAC TCC AAC ATG TGG AAG ATC TGATGTGGAA
1171

5 Glu Pro Leu Met Asp Tyr Ser Asn Met Trp Lys Ile
630 635

GATCTGGAGC GTCTCAGTTT GCTGGTAGCT ATAGATGGGT ATTTGGTTGA TGCTAGCTCT
1231

10 TCGACTGATT AGTTGCTTCA TTAACCTTCG ATTAAGGATT GAGTTAAAAA AAAAAAAAAA
1291

15 AAAA
1295

(2) INFORMATION FOR SEQ ID NO: 12:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 351 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Met Ser Asp Val Thr Ala Val Met Asp Leu Glu Val Glu Glu Pro Gln
1 5 10 15
30 Leu Ala Leu Pro Pro Gly Phe Arg Phe His Pro Thr Asp Glu Glu Val
20 25 30
35 Val Thr His Tyr Leu Thr Arg Lys Val Leu Arg Glu Ser Phe Ser Cys
35 40 45
Gln Val Ile Thr Asp Val Asp Leu Asn Lys Asn Glu Pro Trp Glu Leu
50 55 60
40 Pro Gly Leu Ala Lys Met Gly Glu Lys Glu Trp Phe Phe Phe Ala His
65 70 75 80
Lys Gly Arg Lys Tyr Pro Thr Gly Thr Arg Thr Asn Arg Ala Thr Lys
85 90 95
45 Lys Gly Tyr Trp Lys Ala Thr Gly Lys Asp Lys Glu Ile Phe Arg Gly
100 105 110
Lys Gly Arg Asp Ala Val Leu Val Gly Met Lys Lys Thr Leu Val Phe
115 120 125
50 Tyr Thr Gly Arg Ala Pro Ser Gly Gly Lys Thr Pro Trp Val Met His
130 135 140
55 Glu Tyr Arg Leu Glu Gly Glu Leu Pro His Arg Leu Pro Arg Thr Ala
145 150 155 160
Lys Asp Asp Trp Ala Val Cys Arg Val Phe Asn Lys Asp Leu Ala Ala

	165	170	175
	Arg Asn Ala Pro Gln Met Ala Pro Ala Ala Asp Gly Gly Met Glu Asp		
	180	185	190
5	Pro Leu Ala Phe Leu Asp Asp Leu Leu Ile Asp Thr Asp Leu Phe Asp		
	195	200	205
10	Asp Ala Asp Leu Pro Met Leu Met Asp Ser Pro Ser Gly Ala Asp Asp		
	210	215	220
	Phe Ala Gly Ala Ser Ser Ser Thr Cys Ser Ala Ala Leu Pro Leu Glu		
	225	230	235
15	Pro Asp Ala Glu Leu Pro Val Leu His Pro Gln Gln Gln Gln Ser Pro		
	245	250	255
20	Asn Tyr Phe Phe Met Pro Ala Thr Ala Asn Gly Asn Leu Gly Gly Ala		
	260	265	270
	Glu Tyr Ser Pro Tyr Gln Ala Met Gly Asp Gln Gln Ala Ala Ile Arg		
	275	280	285
25	Arg Tyr Cys Lys Pro Lys Ala Glu Val Ala Ser Ser Ser Ala Leu Leu		
	290	295	300
	Ser Pro Ser Leu Gly Leu Asp Thr Ala Ala Leu Ala Gly Ala Glu Thr		
	305	310	315
30	Ser Phe Leu Met Pro Ser Ser Arg Ser Tyr Leu Asp Leu Glu Glu Leu		
	325	330	335
	Phe Arg Gly Glu Pro Leu Met Asp Tyr Ser Asn Met Trp Lys Ile		
	340	345	350

Applicant's or agent's file reference number	198.091/EXT	International application No.
-------------------------------------------------	-------------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)


A. The indications made below relate to the microorganism referred to in the description on page <u>9</u> , line <u>20</u>	
B. IDENTIFICATION OF DEPOSIT <div style="text-align: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></div>	
Name of depositary institution <div style="text-align: center;">COLECCIÓN ESPAÑOLA DE CULTIVOS TIPO</div>	
Address of depositary institution (including postal code and country) Microbiology Department Biological Science Faculty/UNIVERSITY OF VALENCIA 46100 Burjasot /Valencia/Spain	
Date of deposit <div style="text-align: center;">11th June 1997</div>	Accession Number <div style="text-align: center;">CECT 4889</div>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <div style="text-align: right;">This information is continued on an additional sheet <input type="checkbox"/></div>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

<div style="border-bottom: 1px solid black; padding-bottom: 5px;"> For receiving Office use only </div> <div style="padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application </div> <div style="border-top: 1px solid black; padding-top: 5px;"> Authorized officer <div style="text-align: center; margin-top: 20px;"> </div> <div style="text-align: right; margin-top: 10px;">L.R. Pether</div> </div>	<div style="border-bottom: 1px solid black; padding-bottom: 5px;"> For International Bureau use only </div> <div style="padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border-top: 1px solid black; padding-top: 5px;"> Authorized officer </div>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Applicant's or agent's file reference number	198.091/EXT	International application No
-------------------------------------------------	-------------	------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>9</u> , line <u>21</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution COLECCIÓN ESPAÑOLA DE CULTIVOS TIPO	
Address of depositary institution (including postal code and country) Microbiology Department Biological Science Faculty/UNIVERSITY OF VALENCIA 46100 Burjasot/Valencia/Spain	
Date of deposit 11th June 1997	Accession Number CECT 4890
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer  L.R. Pether	Authorized officer

CLAIMS

1. A method of controlling plant cell cycle characterised in that it comprises increasing or decreasing the levels of, or Geminivirus RepA binding capabilities of,
5 GRAB (Geminivirus RepA Binding) proteins or peptides within a plant cell.

2. A method as claimed in claim 1 characterised in that the control of the plant cell cycle comprises one or more of control of plant cell or plant virus growth and/or replication, plant cell differentiation, development and/or senescence
10

3. A method as claimed in claim 1 or claim 2 characterised in that the GRAB proteins or peptides comprise domains N1, N2, N3, N4 and N5 as shown in figure 4 herein

15 4. A method as claimed in any one of the preceding claims wherein the GRAB proteins or peptides have a first 150 N-terminal amino acids capable of binding to viral RepA protein

5. A method as claimed in any one of the preceding claims characterised in that the
20 GRAB proteins or peptide comprises an amino acid sequence SEQ ID No 3 or 4 as shown herein or a functional variant thereof that is capable of binding Geminivirus RepA

6. A method as claimed in any one of the preceding claims characterised in that it comprises overproducing or underproducing the protein or peptide in a plant cell.

7. A method as claimed in any one of claims 1 to 6 characterised in that it
5 comprises decrease of native GRAB binding activity by application of an agent that binds to GRAB protein or peptide.

8. A method as claimed in any one of the preceding claims characterised in that the
10 GRAB proteins or peptides have amino acid sequence homology of at least 70% with that of SEQ ID No 3 or 4.

9. A method as claimed in any one of the preceding claims comprising placing of
the corresponding GRAB protein or peptide encoding or antisense nucleotides within
the plant cell.

15

10. A method as claimed in claim 9 characterised in that the nucleotides are in the
form of recombinant nucleic acid comprising a GRAB protein or peptide encoding
sequence.

20 11. A method as claimed in claim 10 characterised in that the sequence is positioned
behind a promotor capable of supporting GRAB protein or peptide expression or
production of antisense RNA.

12. A method as claimed in any one of claims 1 to 11 characterised in that the protein or peptide is applied or produced ectopically.

13. A method as claimed in claim 12 characterised in that the tissue is vegetative
5 tissue or stem tissue.

14. A method as claimed in any one of the preceding claims comprising expressing a protein or peptide that is capable of binding to GRAB protein or peptide or functional variant thereof within the cell

10

15. A method as claimed in any preceding claim characterised in that it comprises downregulating native GRAB expression by gene silencing coexpression or through antisense strategy.

15 16. A method as claimed in any one of the preceding claims characterised in that it comprises producing or inhibiting senescence in a plant cell comprising increasing or decreasing the levels or binding activity of a GRAB protein or peptide comprising a sequence of SEQ ID No 10 or a functional variant thereof capable of inducing senescence in *N. bentamiana* plants, in a plant cell

20

17. A method as claimed in claim 16 comprising incorporation of nucleic acid encoding RepA, N-terminal truncated RepA or a functional variant of one of these.

18. A GRAB protein or peptide *per se*, or in enriched, isolated, cell free and/or
25 recombinantly produced form with the proviso that it is not one of SENU, NAM, ATAF1 or ATAF2.

19. A protein or peptide as claimed in claim 18 characterised in it has an N-terminal sequence having 90% or more homology to the first 150 N-terminal amino acids of GRAB1 or GRAB2 described herein or conservatively substituted variants thereof

5 20. A GRAB protein or peptide as claimed in claim 18 characterised in that it comprises an amino acid sequence SEQ ID No 3 or 4 as shown or a functional variant thereof having an amino acid sequence of homology of at least 70% with that sequence that is capable of binding Geminivirus RepA.

10 21. A protein or peptide as claimed in claim 20 characterised in that it comprises a sequence of SEQ ID No 6 or 8 or a functional variant thereof having an amino acid sequence of homology of at least 70% with that sequence.

15 22. A protein or peptide as claimed in claim 21 characterised in that it comprises a sequence of SEQ ID No 10 or 12 or a functional variant thereof having an amino acid sequence of homology of at least 70% with that sequence.

20 23. A GRAB protein or peptide encoding or antisense nucleic acid *per se*, or in enriched, isolated, cell free and/or recombinant form with the proviso that it does not encode the full amino acid sequence of SENU, NAM, ATAF1 or ATAF2

24. Nucleic acid as claimed in claim 23 characterised in that it is in the form of recombinant DNA or cRNA (mRNA) that codes for the expression of a GRAB protein or peptide having an N-terminal sequence with at least 60% homology with the first 200
25 N-terminal amino acids of GRAB1 or GRAB2 as described herein

25 A nucleic acid as claimed in claim 24 characterised in that it is a DNA or RNA polynucleotide comprising one or more of SEQ ID No 1, 2, 5, 7, 9 or 11 or a functional variant thereof

30

26. A method of producing a protein or peptide as claimed in any one of claims 18 to 23 characterised in that it comprises expressing DNA or RNA as described in claim 24 or 25.
- 5 27. A nucleic acid probe or primer characterised in that it comprises an oligonucleotide or polynucleotide of sequence complementary to any 15 or more contiguous bases of the DNA sequences identified herein below as SEQ ID No 5, 7, 9 or 11 or complementary sequences or RNA sequences corresponding thereto.
- 10 28. A nucleic acid transformation vector characterised in that it comprises DNA or RNA as described in any one of claims 9 to 17 or 23 to 25
29. A method for producing transformed cells comprising nucleic acid as claimed in or described in any one of claims 9 to 17 or 23 to 25 comprising introducing said
15 nucleic acid into the cell in vector or free form.
- 30 A method as claimed in claim 29 characterised in that the nucleic acid is introduced directly by electroporation or particle bombardment.
- 20 31 A cell comprising recombinant nucleic acid as described or claimed in any one of claims 9 to 17 or 23 to 25.
- 32 A transgenic plant or part thereof comprising a cell as claimed in claim 31.
- 25 33. A plasmid containing a DNA coding for expression of GRAB protein GRAB 1 or GRAB 2 described herein as deposited under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms of 1977; these being deposited on 11 June 1997 at the Coleccion Espanola de Cultivos Tipo, with the accession numbers CECT 4889 or CECT 4890




FIG 1

FIG 2






Fig 3



	Day 2						Day 3					
p35S.A+B	+	+	+	+	+	+	+	+	+	+	+	+
p35S.GRAB1		+	+				+	+				
p35S.GRAB2					+	+					+	+
GRAB/ A+B ratio		2	6		2	6		2	6		2	6

FIG. 4f

pWoriΔΔ →



N1					
GRAB1	..MVMAAAER	RDAAEALNLP	FGFRFHPTDE	SLVADYLCAR	AAGRAPPVPI
GRAB2	MSDVTAVMDL	EVEEPOLALP	FGFRFHPTDE	SVVTHVLTTR	VLRESFSCQV
ATAF1MSELLQLP	FGFRFHPTDE	SLVTHVLCRR	CASQSIAPVI
ATAF2MKSELNLP	FGFRFHPTDE	SLVKGVLCHK	CASEQISAPV
SENU5MEKVN	FLKNGVLRLP	FGFRFHPTDE	SLVVOVLKRR	VFSFPLPASI
NAM	...MENYQHF	DCSDSN..LP	FGFRFHPTDE	SLITYVLKRS	VLDSNFTGRA
N2		N3			
IAELDLMHFD	PNELPERALF	GAREWYFFTP	RDRKYFNGSR	FNRAAGCGYA	
ITDVDLNRNE	PNELPGLAKM	GEKEWYFFAH	GRKYPICIG	TNRATCKGYW	
IAEIDLKRYD	PNELPGLALY	GEKEWYFFSP	RDRKYFNGSG	FNRSAGSGYA	
IAEIDLKRFN	PNELPEMSLY	GEKEWYFFSP	RDRKYFNGSG	FNRAAGTGYA	
IPVEVYRSC	PNELPGDM..	EQEWYFFST	NEVKYPNGNG	SNRATNSGYW	
IAEVDLNGCE	PNELPEKAKM	GEKEWYFFSL	RDRKYFICIG	TNRATEAGYA	
N4		N5			
KATCAQRP..ARAGRT	VGIRKALVFY	HGRPSAGVKI	DWIMHEYRLA	
KATCKORE..	FRGKGRDAVL	VGKKTILVFY	TGRAPSCQKI	FWIMHEYRLA	
KATCAQRP..GLP.KP	VGIRKALVFY	AGKAPKCEKI	NWIMHEYRLA	
KATCAQRP..GKP.KT	VGIRKALVFY	AGKAPKCEKI	NWIMHEYRLA	
KATGILQI..	LRGRQQQQOL	VGKKTILVFY	RKSPHGCORT	NWIMHEYRLA	
KATCKORE..	YSSKT..SAL	VGKKTILVFY	RGRAPKCEKS	NWIMHEYRLD	
GADGRA.AKN	GGTLRLDEAV	FORLYNK...	KNQWEKMR	
GELP.HRLPR	TAK...DIAA	VORVENDLA	ARNAPOMAPA	ADGGMEDPLA	
DVDRSVR.KK	KNSLRLEDV	FORLYNK...	KGATERRGP	
NDRSASVVK	KNNLRLDEAV	FORLYNK...	KGTMEKYFP	
NLESNYHPIQGNAV	FORIFLKRKRG	NTKNKEENMT	THDEVNRREI	
GKFAYHYISR	SSK...DEAV	VSERVEOK...	..SCSTVGT	SNGGKKRLNS	
ORQ.....	.EEEEAAKAA	ASQSVSWGET	RTPESDVD..NDPF	
FLDILLIDTO	LFDDADLPML	MDSPSGADDF	AGASSSTCSA	ALPLEPDAEL	
PPPVVGDEI	MEEKPKVTEM	VMPPPPQOTS	EFAYFDT...DSV..	
A.....	.DEKPRTTIM	AEQSSSP...FDT...DSTY	
DKNSPVVSVK	MSSRDSEALA	SANSELKKKA	SIIFYD....	...FMGRNNS	
SFNNMYQEV	SPSSVSLPPL	LESSPYNN..TATSAA	ASKKEHVSCF	
PELDSL.PEF	QTANASILPK	SEVOELGNDD	WLMGI.SLDD	LQPGSLMLP	
PVLPQQQQS	PNYFFMPATA	NGNLGGAEYS	PYQAMGDQQA	AIRRYCKPKA	
PKLHTDSSC	S...EQVSP	EFTSEVQSEP	KWKDW.SAVS	NDNNNTLDFG	
PTLQEDDSSS	SGGHGHVSP	IVL.EVQSEP	KWGELEDALE	AFDTSMLVVP	
KQVAASTSSS	GITDLTTTNE	ESDDHEESTS	SFNNFTTFKR	KIN.....	
STLSTPSFDP	SSVFDISSNS	NT.LHSLPAP	SFSAILDPSS	TFSRNSVFP	
WD.....DSYAAS	FLSPVATMCM	BQDVSPFFF..	
EVASSSALLS	PSLGLDTAAL	AGAETSFLMP	SSRSYLDLEE	LFRGEPLMDY	
FNYIDATVDN	AFGGGGSSNQ	MFPLQDMFY	HQKPY.....	
WCCSLTL..	.LSLSSCISL	IISLPSRIRL	SRNHS.....	
.....	
LRLQENLHL	PLFSGGTSAM	HGGFSSPLAN	WPVPETQKVD	HSELDOMWSY	

SNMWKI

FIG.5




FIG. 6

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/82, C07K 14/415	A3	(11) International Publication Number: WO 98/56811 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/EP98/03662 (22) International Filing Date: 9 June 1998 (09.06.98) (30) Priority Data: P 9701292 12 June 1997 (12.06.97) ES (71) Applicant (for all designated States except US): CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS [ES/ES]; Serrano, 113, E-28006 Madrid (ES). (72) Inventors; and (75) Inventors/Applicants (for US only): GUTIERREZ-ARMENTA, Crisanto [ES/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). Qi, Xie [CN/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). SANZ-BURGOS, Andrés [ES/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). (74) Agent: UNGRIA-LOPEZ, Javier; Ungría Patentes y Marcas, S.A., Avenida Ramón y Cajal, 78, E-28043 Madrid (ES).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 4 March 1999 (04.03.99)
(54) Title: PLANT GRAB PROTEINS (57) Abstract <p>A method of controlling plant cell and plant virus growth and/or replication, plant cell cycle, differentiation, development and/or senescence is provided characterised in that it comprises increasing or decreasing the levels or binding capabilities of GRAB (Geminivirus RepA Binding) proteins other than Rb (Retinoblastoma) proteins within plant cells.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03662

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/82 C07K14/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	XIE Q ET AL: "PLANT CELLS CONTAIN A NOVEL MEMBER OF THE RETINOBLASTOMA FAMILY OF GROWTH REGULATORY PROTEINS" EMBO JOURNAL., vol. 15, no. 18, 16 September 1996, pages 4900-4908, XP002042541 EYNHAM, OXFORD GB see the whole document, especially page 4901 - page 4903 --- -/--	1-4,6, 10,11, 18,23, 26,28-32

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 December 1998

Date of mailing of the international search report

21/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

Int. Application No.
PCT/EP 98/03662

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	XIE A ET AL: "IDENTIFICATION AND ANALYSIS OF A RETINOBLASTOMA BINDING MOTIF IN THE REPLICATION PROTEIN OF A PLANT DNA VIRUS: REQUIREMENT FOR EFFICIENT VIRAL DNA REPLICATION" EMBO JOURNAL., vol. 14, no. 16, 15 August 1995, pages 4073-4082, XP002042538 EYNHAM, OXFORD GB cited in the application see the whole document, especially page 4079 - page 4080	1
A	---	17
Y	FIELDS S ET AL: "THE TWO-HYBRID SYSTEM: AN ASSAY FOR PROTEIN-PROTEIN INTERACTIONS" TRENDS IN GENETICS., vol. 10, no. 8, August 1994, pages 286-292, XP000647708 AMSTERDAM NL see the whole doculemnt, especially page 288 - page 289	1
A	---	1
A	GRAFI G ET AL: "A MAIZE CDNA ENCODING A MEMBER OF THE RETINOBLASTOMA PROTEIN FAMILY: INVOLVEMENT IN ENDOREDUPLICATION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 93, no. 17, 20 August 1996, pages 8962-8967, XP002042542 WASHINGTON US see the whole document	1
A	---	1,18,23
A	AIDA M ET AL: "Arabidopsis thaliana DNA for CUC2" EMBL SEQUENCE DATABASE, 10 April 1997, XP002085516 HEIDELBERG DE Accession Nr.: AB002560 see abstract	1,18,23
A	---	1,18,23
A	RUETH J ET AL: "Arabidopsis thaliana ATAF1 mRNA" EMBL SEQUENCE DATABASE, 9 September 1993, XP002085517 HEIDELBERG DE Accession Nr.: X74755 see abstract	1,18,23

	-/--	

INTERNATIONAL SEARCH REPORT

Inter. Application No.

PCT/EP 98/03662

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RUETH J ET AL: "Arabidopsis thaliana ATAF2 mRNA" EMBL SEQUENCE DATABASE, 3 September 1993, XP002085518 HEIDELBERG DE Accession Nr.: X74756 see abstract ---	1,18,23
P,X	WO 97 47745 A (CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS) 18 December 1997 see the whole document ---	1-4,6, 10,11, 18,23, 26,28-32
P,X	WO 97 47647 A (CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS) 18 December 1997 see the whole document -----	1-4,6, 10,11, 18,23, 26,28-32

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03662

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9747745	A	18-12-1997	WO 9747647	A	18-12-1997
			AU 3257997	A	07-01-1998
<hr/>					
WO 9747647	A	18-12-1997	AU 3257997	A	07-01-1998
			WO 9747745	A	18-12-1997
<hr/>					

Form PCT/ISAR/210 (patent family annex) (July 1994)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/82, C07K 14/415	A3	(11) International Publication Number: WO 98/56811 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/EP98/03662 (22) International Filing Date: 9 June 1998 (09.06.98) (30) Priority Data: P 9701292 12 June 1997 (12.06.97) ES (71) Applicant (for all designated States except US): CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS [ES/ES]; Serrano, 113, E-28006 Madrid (ES). (72) Inventors; and (75) Inventors/Applicants (for US only): GUTIERREZ-ARMENTA, Crisanto [ES/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). Qi, Xie [CN/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). SANZ-BURGOS, Andrés [ES/ES]; Centro de Biología Molecular, CSIC-UAM, E-28049 Madrid (ES). (74) Agent: UNGRIA-LOPEZ, Javier, Ungria Patentes y Marcas, S.A., Avenida Ramón y Cajal, 78, E-28043 Madrid (ES).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i> (88) Date of publication of the international search report: 4 March 1999 (04.03.99) Date of publication of the amended claims: 8 April 1999 (08.04.99)
(54) Title: PLANT GRAB PROTEINS (57) Abstract A method of controlling plant cell and plant virus growth and/or replication, plant cell cycle, differentiation, development and/or senescence is provided characterised in that it comprises increasing or decreasing the levels or binding capabilities of GRAB (Gemünivirus RepA Binding) proteins other than Rb (Retinoblastoma) proteins within plant cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AMENDED CLAIMS

[received by the International Bureau on 22 February 1999 (22.02.99);
original claims 1-33 replaced by amended claims 1-32 (6 pages)]

1. A method of controlling plant cell cycle characterised in that it comprises increasing or decreasing the levels of, or Geminivirus RepA binding capabilities of, GRAB (Geminivirus RepA Binding) protein or peptide within a plant cell characterised in that the GRAB protein or peptide comprises domains N1, N2, N3, N4 and N5 shown in Figure 5 herein which have the designated amino acids shown in SEQ ID No 3 and SEQ ID 4.
2. A method as claimed in claim 1 characterised in that the control of the plant cell cycle comprises one or more of control of plant cell or plant virus growth and/or replication, plant cell differentiation, development and/or senescence.
3. A method as claimed in any one of the preceding claims wherein the GRAB proteins or peptides have a first 150 N-terminal amino acids capable of binding to viral RepA protein.
4. A method as claimed in any one of the preceding claims characterised in that the GRAB proteins or peptide comprises an amino acid sequence SEQ ID No 3 or 4 as shown herein or a functional variant thereof that is capable of binding Geminivirus RepA.
5. A method as claimed in any one of the preceding claims characterised in that it comprises overproducing or underproducing the protein or peptide in a plant cell.

6. A method as claimed in any one of claims 1 to 5 characterised in that it comprises decrease of native GRAB binding activity by application of an agent that binds to GRAB protein or peptide.

5

7. A method as claimed in any one of the preceding claims characterised in that the GRAB proteins or peptides have amino acid sequence homology of at least 70% with that of SEQ ID No 3 or 4.

10 8. A method as claimed in any one of the preceding claims comprising placing of the corresponding GRAB protein or peptide encoding or antisense nucleotides within the plant cell.

9. A method as claimed in claim 8 characterised in that the nucleotides are in the
15 form of recombinant nucleic acid comprising a GRAB protein or peptide encoding sequence.

10. A method as claimed in claim 9 characterised in that the sequence is positioned
behind a promotor capable of supporting GRAB protein or peptide expression or
20 production of antisense RNA.

11. A method as claimed in any one of claims 1 to 10 characterised in that the protein or peptide is applied or produced ectopically.

12. A method as claimed in claim 11 characterised in that the tissue is vegetative tissue or stem tissue.

13. A method as claimed in any one of the preceding claims comprising expressing
5 a protein or peptide that is capable of binding to GRAB protein or peptide or functional variant thereof within the cell.

14. A method as claimed in any preceding claim characterised in that it comprises
downregulating native GRAB expression by gene silencing coexpression or through
10 antisense strategy.

15. A method as claimed in any one of the preceding claims characterised in that it
comprises producing or inhibiting senescence in a plant cell comprising increasing or
decreasing the levels or binding activity of a GRAB protein or peptide comprising a
15 sequence of SEQ ID No 10 or a functional variant thereof capable of inducing
senescence in *N.bentamiana* plants. in a plant cell.

16. A method as claimed in claim 15 comprising incorporation of nucleic acid
encoding RepA, N-terminal truncated RepA or a functional variant of one of these.
20

17. A GRAB protein or peptide *per se*, or in enriched, isolated, cell free and/or
recombinantly produced form characterised in that characterised in that the GRAB
protein or peptide comprises domains N1, N2, N3, N4 and N5 shown in Figure 5 herein
which have the designated amino acids shown in SEQ ID No 3 and SEQ ID 4 and with
25 the proviso that it is not one of SENU, NAM, ATAF1 or ATAF2.

18. A protein or peptide as claimed in claim 17 characterised in it has an N-terminal sequence having 90% or more homology to the first 150 N-terminal amino acids of GRAB1 or GRAB2 described herein or conservatively substituted variants thereof.
- 5 19. A GRAB protein or peptide as claimed in claim 17 characterised in that it comprises an amino acid sequence SEQ ID No 3 or 4 as shown or a functional variant thereof having an amino acid sequence of homology of at least 70% with that sequence that is capable of binding Geminivirus RepA.
- 10 20. A protein or peptide as claimed in claim 19 characterised in that it comprises a sequence of SEQ ID No 6 or 8 or a functional variant thereof having an amino acid sequence of homology of at least 70% with that sequence.
21. A protein or peptide as claimed in claim 20 characterised in that it comprises a
15 sequence of SEQ ID No 10 or 12 or a functional variant thereof having an amino acid sequence of homology of at least 70% with that sequence.
22. A GRAB protein or peptide encoding or antisense nucleic acid *per se*, or in enriched, isolated, cell free and/or recombinant form
20 characterised in that the GRAB protein or peptide comprises domains N1, N2, N3, N4 and N5 shown in Figure 5 herein which have the designated amino acids shown in SEQ ID No 3 and SEQ ID 4 and with the proviso that it does not encode the full amino acid
sequence of SENU, NAM, ATAF1 or ATAF2.
- 25 23. Nucleic acid as claimed in claim 22 characterised in that it is in the form of recombinant DNA or cRNA (mRNA) that codes for the expression of a GRAB protein or peptide having an N-terminal sequence with at least 60% homology with the first 200 N-terminal amino acids of GRAB1 or GRAB2 as described herein

24. A nucleic acid as claimed in claim 23 characterised in that it is a DNA or RNA polynucleotide comprising one or more of SEQ ID No 1, 2, 5, 7, 9 or 11 or a functional variant thereof

5 25. A method of producing a protein or peptide as claimed in any one of claims 18 to 23 characterised in that it comprises expressing DNA or RNA as described in claim 23 or 24.

10 26. A nucleic acid probe or primer characterised in that it comprises an oligonucleotide or polynucleotide of sequence complementary to any 15 or more contiguous bases of the DNA sequences identified herein below as SEQ ID No 5, 7, 9 or 11 or complementary sequences or RNA sequences corresponding thereto.

15 27. A nucleic acid transformation vector characterised in that it comprises DNA or RNA as described in any one of claims 8 to 16 or 22 to 24.

20 28. A method for producing transformed cells comprising nucleic acid as claimed in or described in any one of claims 8 to 16 or 22 to 24 comprising introducing said nucleic acid into the cell in vector or free form.

29. A method as claimed in claim 28 characterised in that the nucleic acid is introduced directly by electroporation or particle bombardment.

25 30. A cell comprising recombinant nucleic acid as described or claimed in any one of claims 8 to 16 or 22 to 24.

31. A transgenic plant or part thereof comprising a cell as claimed in claim 30.

30 32. A plasmid containing a DNA coding for expression of GRAB protein GRAB 1 or GRAB 2 described herein as deposited under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms of 1977; these being

deposited on 11 June 1997 at the Coleccion Espanola de Cultivos Tipo, with the accession numbers CECT 4889 or CECT 4890 .